ClinicalTrials.gg
CompletedNCT02212457Updated Jun 27, 2019Results posted

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

A Phase 2 interventional study of Bexsero and Saline Placebo in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 32 sites in 3 countries. Open to participants aged 10 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-27.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,063
Allocation
Randomized
Ages
10 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
7th of 21
1,063 · median 508
Started
2014
with 2 others
Phase 2
7 of 21
1 open now
Registered
14th of 21
by date
Lead sponsor
6 of 21
GlaxoSmithKline

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 7th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 14th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 10 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

The main purposes for conducting the study are firstly to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those of the licensed rMenB+OMV vaccine (Bexsero™) in terms of hSBA GMTs at one month after the second vaccination, secondly to give the flexibility for the national vaccination program by showing the safety and immunogenicity of MenABCWY administrated according to four different vaccination schedules and additionally to evaluate a potential benefit of the 3-dose vaccination series.

03

Conditions studied

  • Infections, Meningococcal
04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adolecents from 10-18 yearsof age, generally in good health, and available for all study visits, and who/whose legally acceptable representative has given written at the time of enrollment.
  2. Individuals of who the investigator believes can and will comply with the requirements of the protocol (e.g. use of an eDiary, return for follow-up visits, available for phone contacts).
  3. Female subjects of must have a negative urine preganancy test.

Exclusion criteria

Exclusion Criteria:

  1. Serious, acute, or chronic illness. Previous or suspected disease caused by N. meningitidis. Previous immunization with any menincococcal or Hepatitis A vaccines.
  2. Exposure to individuals with clicically proven meningococcal disease or clinical bacterial meningitis without further microbiologic characteriszation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,063 participants (actual)

Study arms

  • Experimental
    rMenB_0_2 Group

    Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.

    Biological: Bexsero · Other: Saline Placebo · Biological: Havrix

  • Experimental
    ABCWY_ 0_2 Group

    Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.

    Other: Saline Placebo · Biological: Havrix · Biological: MenABCWY

  • Experimental
    ABCWY_0_1 Group

    Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.

    Other: Saline Placebo · Biological: Havrix · Biological: MenABCWY

  • Experimental
    ABCWY_0_6 Group

    Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.

    Other: Saline Placebo · Biological: Havrix · Biological: MenABCWY

  • Experimental
    ABCWY_0_11 Group

    Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.

    Other: Saline Placebo · Biological: Havrix · Biological: MenABCWY

  • Experimental
    ABCWY_0_2_6 Group

    Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.

    Biological: Havrix · Biological: MenABCWY

Interventions

  • BiologicalBexsero

    Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.

  • OtherSaline Placebo

    One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.

  • BiologicalHavrix

    Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

  • BiologicalMenABCWY

    Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.

06

What researchers measure

Primary outcomes

  1. Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.

    The non-inferiority of the Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant (MenABCWY) vaccine to Meningococcal (group B) multicomponent recombinant adsorbed (Bexsero) vaccine, administered according to 0, 2 month schedule, as measured by hSBA GMTs against N.meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, is reported. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the rMenB_0_2 and ABCWY_ 0_2 Groups.

    Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3)

Secondary outcomes

  1. hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.

    The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 2 months schedule, as measured by hSBA GMTs against N. meningitidis serogroup B test strains and serogroups A,C, W and Y at 1 month after the last meningococcal vaccination. The B test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the ABCWY_ 0_2 and ABCWY_0_2_6 Groups. 1 month post last meningococcal vaccination corresponds to Month 3 for ABCWY_0_2 Group and Month 7 for ABCWY_0_2_6 Group.

    Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group)

  2. Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.

    The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 2 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination.

    Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group)

  3. hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule.

    The immunogenicity of MenABCWY vaccine, administered according to 0, 2 months schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.

    Time frame: At 1 Month after the last vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group, Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group)

  4. Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.

    A sufficient immune response following Bexsero vaccine, administered according to 0, 2 month schedule, as measured by the percentage of subjects with hSBA titers ≥ Lower Limit of Quantitation (LLQ) against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, was to be demonstrated. Criterion: the immune response was to be considered sufficient if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA titers ≥ LLQ was greater than 75% for each of the four serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.

    Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3)

  5. hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.

    The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 6 months schedule, as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.

    Time frame: At 1 month after last vaccination (Month 7)

  6. Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.

    The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 6 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.

    Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 7)

  7. Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule.

    The immunogenicity of MenABCWY vaccine, administered according to 0, 2 month schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.

    Time frame: At 1 month after second vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group , Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group)

  8. hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the adjusted hSBA GMTs against serogroups A,C, W and Y and serogroup B test strains was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13

  9. Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against NZ98/254 B strain was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.

  10. Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M14459 B strain was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.

  11. Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M07-0241084 B strain was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.

  12. Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against 96217 B strain was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.

  13. Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against A human serogroup was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.

  14. Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against C human serogroup was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.

  15. Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against W human serogroup was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.

  16. Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules.

    The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against Y human serogroup was assessed.

    Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.

  17. Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules.

    The kinetic of immune response (at Months 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with two-, three- and four-fold titer rise against serogroups A, C, W and Y and serogroup B test strains was assessed. The two/three/four fold titer rise is defined as: a) for subjects with prevaccination hSBA titers ≤ LLQ, a postvaccination hSBA ≥ 2/3/4 LLQ; b) for subjects with a prevaccination hSBA titers ≥ LLQ, an increase of at least 2/3/4 times of the prevaccination hSBA titer.

    Time frame: At Month 2, Month 3, Month 7 and Month 13

  18. The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains.

    The area under the curve for percentage of subjects with hSBA titers ≥ LLQ for all serogroups (A, C, W and Y) and for all serogroup B test strains (M14459, 96217, NZ98/254 and M07-0241084) was summarized overall (from Month 0 to Month 13) and by period (from Month 0 to Month 2, Month 2 to Month 3, Month 3 to Month 7 and Month 7 to Month 13) by vaccine groups. It was computed as the sum of the trapezoidal areas and the time unit used was the month. AUC 0_13 = (r0+r2)(2-0)/2 + (r2+r3)(3-2)/2 + (r3+r7)(7-3)/2 + (r7+r13)(13-7)/2 with ri = percentages of subjects with both hSBA titers \>= LLQ against N. meningitis for all serogroups A, C, W and Y and for all serogroup B test strains at Month 1.

    Time frame: From Month 0 to Month 13

  19. Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination.

    Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity within 30 minutes after each vaccination. Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).

    Time frame: Within 30 minutes after vaccination

  20. Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination.

    An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a participant and/or parent/legal guardian who has signed the informed consent. Number of participants reporting any unsolicited AE within 30 minutes after each vaccination.

    Time frame: Within 30 minutes after vaccination

  21. Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination.

    The number of participants reporting unsolicited AEs and possibly or probably related unsolicited AEs were assessed.

    Time frame: Day 1 through Day 30 after any vaccination

  22. Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7.

    Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity from Day 1 (6 hours) to Day 7 after any meningococcal vaccination is reported.

    Time frame: At Day 1 (6 hours) to Day 7 after vaccination

  23. Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal

    The number of participants reporting any SAE, possibly or probably related SAE(s), medically-attended AEs, AEs leading to premature withdrawal, AEs leading to death, AEs leading to hospitalization and AEs leading to dose reduction, interruption and delay in study vaccination during the entire study period is reported.

    Time frame: During the entire study period (Month 0 to Month 13)

07

Results

Posted Jul 21, 2017

Participant flow

Subjects were recruited from 32 centers from Finland, Poland and United States.

Participant flow — Overall Study
MilestonerMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Started228232157134152160
Completed209211141123137147
Not completed192116111513
Withdrew: Adverse event122201
Withdrew: Withdrawal by subject8108654
Withdrew: Lost to follow-up674184
Withdrew: Protocol violation210123
Withdrew: Other212101

Outcome measures

PrimaryHuman Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.

The non-inferiority of the Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant (MenABCWY) vaccine to Meningococcal (group B) multicomponent recombinant adsorbed (Bexsero) vaccine, administered according to 0, 2 month schedule, as measured by hSBA GMTs against N.meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, is reported. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the rMenB_0_2 and ABCWY_ 0_2 Groups.

Time frame:
At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3)
Reported as:
Geometric mean · Titers
Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.
TitersABCWY_ 0_2 GrouprMenB_0_2 Group
M14459 strain (Month 0)1.28 (1.07 to 1.53)1.31 (1.09 to 1.57)
M14459 strain (Month 3)11.64 (8.61 to 16)15.78 (12 to 22)
M07-0241084 strain (Month 0)2.12 (1.60 to 2.82)2.16 (1.61 to 2.89)
M07-0241084 strain (Month 3)8.19 (6.31 to 11)11.56 (8.86 to 15)
96217 strain (Month 0)2.93 (2.13 to 4.03)2.36 (1.70 to 3.28)
96217 strain (Month 3)150.82 (118 to 192)229.29 (179 to 294)
NZ98/254 strain (Month 0)1.27 (1.06 to 1.53)1.15 (0.95 to 1.39)
NZ98/254 strain (Month 3)11.95 (9.10 to 16)24.31 (18 to 32)
Statistical analysis
  • ABCWY_ 0_2 Group vs rMenB_0_2 Group · ANCOVA · Geometric mean ratio: 0.74 · 95% CI 0.53 to 1.02
  • ABCWY_ 0_2 Group vs rMenB_0_2 Group · ANCOVA · Geometric mean ratio: 0.71 · 95% CI 0.54 to 0.94
  • ABCWY_ 0_2 Group vs rMenB_0_2 Group · ANCOVA · Geometric mean ratio: 0.66 · 95% CI 0.51 to 0.85
  • ABCWY_ 0_2 Group vs rMenB_0_2 Group · ANCOVA · Geometric mean ratio: 0.49 · 95% CI 0.37 to 0.66
SecondaryhSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.

The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 2 months schedule, as measured by hSBA GMTs against N. meningitidis serogroup B test strains and serogroups A,C, W and Y at 1 month after the last meningococcal vaccination. The B test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the ABCWY_ 0_2 and ABCWY_0_2_6 Groups. 1 month post last meningococcal vaccination corresponds to Month 3 for ABCWY_0_2 Group and Month 7 for ABCWY_0_2_6 Group.

Time frame:
At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group)
Reported as:
Geometric mean · Titers
hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.
TitersABCWY_ 0_2 GroupABCWY_0_2_6 Group
M14459 strain (Month 0)1.21 (1.07 to 1.37)1.12 (0.98 to 1.28)
M14459 strain (Month 3/Month 7)12.17 (9.60 to 15)27.09 (21 to 35)
M07-0241084 strain (Month 0)2.36 (1.85 to 3.01)2.05 (1.58 to 2.67)
M07-0241084 strain (Month 3/Month 7)8.91 (7.10 to 11)18.03 (14 to 23)
96217 strain (Month 0)2.31 (1.75 to 3.06)2.28 (1.68 to 3.07)
96217 strain (Month 3/Month7)174.27 (142 to 215)298.76 (239 to 374)
NZ98/254 strain (Month 0)1.24 (1.09 to 1.41)1.07 (0.93 to 1.23)
NZ98/254 strain (Month 3/Month7)12.57 (9.81 to 16)17.55 (13 to 23)
A human serogroup (Month 0)1.19 (1.04 to 1.36)1.10 (0.95 to 1.27)
A human serogroup (Month 3/Month7)66.73 (54 to 83)125.45 (99 to 159)
C human serogroup (Month 0)3.59 (2.85 to 4.53)3.19 (2.48 to 4.10)
C human serogroup (Month 3/Month7)158.8 (127 to 199)376.44 (295 to 481)
W human serogroup (Month 0)5.20 (3.56 to 7.59)4.64 (3.05 to 7.05)
W human serogroup (Month 3/Month7)206.62 (175 to 244)295.9 (246 to 356)
Y human serogroup (Month 0)1.33 (1.10 to 1.60)1.26 (1.03 to 1.55)
Y human serogroup (Month 3/Month7)79.84 (62 to 103)163.69 (124 to 216)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.

The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 2 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination.

Time frame:
At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.
Percentages of subjectsABCWY_ 0_2 GroupABCWY_0_2_6 Group
NZ98/254 strain (Month 0)6 (3.37 to 10.45)2 (0.41 to 5.70)
NZ98/254 strain (Month 3/7)63 (55.85 to 69.26)74 (65.72 to 80.35)
M14459 strain (Month 0)5 (2.68 to 9.31)2 (0.41 to 5.70)
M14459 strain (Month 3/Month 7)70 (63.48 to 76.23)89 (83.36 to 93.82)
M07-0241084 strain (Month 0)18 (13.30 to 24.47)18 (12.06 to 25.16)
M07-0241084 strain (Month 3/7)49 (41.54 to 55.59)72 (64.35 to 79.33)
96217 strain (Month 0)28 (22.24 to 34.99)27 (20.02 to 35.11)
96217 strain (Month 3/7)97 (93.25 to 98.65)99 (96.34 to 99.98)
Serogroup A (Month 0)3 (1.08 to 6.23)1 (0.02 to 3.76)
Serogroup A (Month 3/7)88 (83.01 to 92.18)95 (89.56 to 97.62)
Serogroup C (Month 0)44 (37.28 to 51.24)41 (32.62 to 49.15)
Serogroup C (Month 3/7)99 (96.63 to 99.89)100 (97.55 to 100)
Serogroup W (Month 0)27 (21.20 to 34.04)22 (15.17 to 29.56)
Serogroup W (Month 3/7)97 (93.19 to 98.64)99 (96.08 to 99.98)
Serogroup Y (Month 0)9 (5.37 to 13.72)6 (2.78 to 11.08)
Serogroup Y (Month 3/7)92 (86.97 to 94.91)97 (93.31 to 99.27)
SecondaryhSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule.

The immunogenicity of MenABCWY vaccine, administered according to 0, 2 months schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.

Time frame:
At 1 Month after the last vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group, Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group)
Reported as:
Geometric mean · Titers
hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule.
TitersABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 Group
NZ98/254 strain12.32 (9.82 to 15)6.33 (4.86 to 8.23)13.64 (10 to 18)15.87 (12 to 21)
M14459 strain12.72 (10 to 16)9.19 (7.11 to 12)26.48 (20 to 35)29.57 (23 to 39)
M07-0241084 strain9.15 (7.52 to 11)6.59 (5.25 to 8.27)15.04 (12 to 19)16.22 (13 to 21)
96217 strain165.47 (133 to 206)117.28 (91 to 151)237.89 (182 to 310)244.97 (189 to 317)
A human serogroup69.61 (56 to 87)79.87 (62 to 103)140.76 (108 to 184)162.76 (126 to 211)
C human serogroup162.57 (132 to 201)145.73 (114 to 186)225.00 (174 to 290)292.61 (227 to 376)
W human serogroup215.72 (182 to 256)197.69 (162 to 241)376.03 (306 to 462)531.79 (434 to 652)
Y human serogroup71.66 (55 to 93)57.45 (42 to 78)120.76 (88 to 166)209.53 (153 to 286)
SecondaryPercentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.

A sufficient immune response following Bexsero vaccine, administered according to 0, 2 month schedule, as measured by the percentage of subjects with hSBA titers ≥ Lower Limit of Quantitation (LLQ) against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, was to be demonstrated. Criterion: the immune response was to be considered sufficient if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA titers ≥ LLQ was greater than 75% for each of the four serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.

Time frame:
At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 Group
NZ98/254 strain - month 0 (LLQ = 8.2)7 (3.73 to 11.53)6 (3.40 to 11.06)
NZ98/254 strain - month 3 (LLQ = 8.2)88 (82.82 to 92.52)61 (53.65 to 68.15)
M14459 strain - month 0 (LLQ = 8.0)7 (3.41 to 11.11)5 (2.32 to 9.33)
M14459 strain - month 3 (LLQ = 8.0)82 (75.75 to 87.32)68 (60.21 to 74.39)
M07-0241084 strain - month 0 (LLQ = 8.9)21 (15.19 to 27.25)18 (12.78 to 24.69)
M07-0241084 strain - month 3 (LLQ = 8.9)66 (59.26 to 73.19)47 (39.60 to 54.81)
96217 strain - month 0 (LLQ = 8.6)23 (17.26 to 29.85)29 (22.14 to 35.89)
96217 strain - month 3 (LLQ = 8.6)99 (97.04 to 99.99)97 (92.81 to 98.75)
SecondaryhSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.

The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 6 months schedule, as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.

Time frame:
At 1 month after last vaccination (Month 7)
Reported as:
Geometric mean · Titers
hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.
TitersABCWY_0_6 GroupABCWY_0_2_6 Group
NZ98/254 strain13.62 (9.98 to 19)17.13 (13 to 23)
M14459 strain27.82 (21 to 36)29.27 (23 to 37)
M07-0241084 strain17.43 (13 to 23)20.92 (16 to 27)
96217 strain240.13 (186 to 310)291.63 (232 to 367)
Serogroup A140.14 (107 to 184)128.75 (101 to 164)
Serogroup C246.48 (191 to 318)413.60 (328 to 522)
Serogroup W341.90 (283 to 413)282.74 (237 to 338)
Serogroup Y123.96 (91 to 169)151.36 (115 to 200)
SecondaryPercentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.

The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 6 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.

Time frame:
At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 7)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.
Percentages of subjectsABCWY_0_6 GroupABCWY_0_2_6 Group
NZ98/254 strain - month 0 (LLQ=8.2)5 (1.86 to 10.57)2 (0.41 to 5.70)
NZ98/254 strain - month 7 (LLQ=8.2)64 (55.25 to 72.95)74 (65.72 to 80.35)
M14459 strain - month 0 (LLQ=8.0)5 (1.84 to 10.48)2 (0.41 to 5.70)
M14459 strain - month 7 (LLQ=8.0)87 (79.58 to 92.31)89 (83.36 to 93.82)
M07-0241084 strain - month 0 (LLQ=8.9)14 (8.33 to 21.37)18 (12.06 to 25.16)
M07-0241084 strain - month 7 (LLQ=8.9)66 (56.76 to 74.16)72 (64.35 to 79.33)
96217 strain - month 0 (LLQ=8.6)27 (19.18 to 35.79)27 (20.02 to 35.11)
996217 strain - month 7 (LLQ=8.6)98 (92.93 to 99.49)99 (96.34 to 99.98)
A human serogroup - month 0 (LLQ=22.7)2 (0.21 to 5.99)1 (0.02 to 3.76)
A human serogroup - month 7 (LLQ=22.7)94 (88.63 to 97.68)95 (89.56 to 97.62)
C human serogroup - month 0 (LLQ=5.2)42 (32.94 to 51.07)41 (32.62 to 49.15)
C human serogroup - month 7 (LLQ=5.2)99 (95.55 to 99.98)100 (97.55 to 100)
W human serogroup - month 0 (LLQ=39.6)20 (13.37 to 28.51)22 (15.17 to 29.56)
W human serogroup -month 7 (LLQ=39.6)99 (95.55 to 99.98)99 (96.08 to 99.98)
Y human serogroup - month 0 (LLQ=14.7)7 (2.92 to 12.71)6 (2.78 to 11.08)
Y human serogroup - month 7 (LLQ=14.7)94 (88.63 to 97.68)97 (93.31 to 99.27)
SecondaryPercentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule.

The immunogenicity of MenABCWY vaccine, administered according to 0, 2 month schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.

Time frame:
At 1 month after second vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group , Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group)
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule.
Percentages of subjectsABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 Group
NZ98/254 strain (LLQ=8.2)63 (55.85 to 69.26)44 (35.36 to 52.23)64 (55.25 to 72.95)73 (64.85 to 80.63)
M14459 strain (LLQ=8.0)70 (63.48 to 76.23)62 (53.56 to 70.20)87 (79.58 to 92.31)89 (82.08 to 93.55)
M07-0241084 strain (LLQ=8.9)49 (41.54 to 55.59)40 (31.82 to 48.61)66 (56.76 to 74.16)69 (60.82 to 77.21)
96217 strain (LLQ=8.6)97 (93.25 to 98.65)97 (92.99 to 99.23)98 (92.93 to 99.49)98 (93.55 to 99.53)
Serogroup A (LLQ=22.7)88 (83.01 to 92.18)92 (85.70 to 95.56)94 (88.63 to 97.68)94 (88.49 to 97.37)
Serogroup C (LLQ=5.2)99 (96.63 to 99.89)100 (97.44 to 100)99 (95.55 to 99.99)100 (97.22 to 100)
Serogroup W (LLQ=39.6)97 (93.19 to 98.64)96 (91.09 to 98.44)99 (95.55 to 99.98)98 (93.45 to 99.53)
Serogroup Y (LLQ=14.7)92 (86.97 to 94.91)85 (78.29 to 90.61)94 (88.63 to 97.68)97 (92.42 to 99.17)
SecondaryhSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the adjusted hSBA GMTs against serogroups A,C, W and Y and serogroup B test strains was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13
Reported as:
Geometric mean · Titers
hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules.
TitersrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
NZ98/254 strain (Month 0)1.22 (1.08 to 1.38)1.22 (1.08 to 1.38)1.21 (1.04 to 1.40)1.13 (0.97 to 1.31)1.12 (0.97 to 1.29)1.06 (0.93 to 1.22)
NZ98/254 strain (Month 2)2.67 (2.14 to 3.34)2.27 (1.82 to 2.84)6.50 (4.98 to 8.48)1.92 (1.46 to 2.51)3.87 (2.98 to 5.01)2.20 (1.71 to 2.82)
NZ98/254 strain (Month 3)27.17 (22 to 34)11.46 (9.28 to 14)3.15 (2.44 to 4.05)1.69 (1.31 to 2.19)2.38 (1.86 to 3.05)12.80 (10 to 16)
NZ98/254 strain (Month 7)3.00 (2.44 to 3.67)2.41 (1.97 to 2.95)1.88 (1.47 to 2.40)14.30 (11 to 18)1.75 (1.38 to 2.22)18.24 (14 to 23)
NZ98/254 strain (Month 13)2.33 (1.92 to 2.83)1.93 (1.59 to 2.33)1.81 (1.44 to 2.27)2.57 (2.04 to 3.25)17.08 (14 to 21)2.82 (2.28 to 3.51)
M14459 strain(Month 0)1.37 (1.21 to 1.56)1.22 (1.08 to 1.39)1.22 (1.04 to 1.42)1.21 (1.04 to 1.41)1.34 (1.15 to 1.55)1.17 (1.02 to 1.35)
M14459 strain (Month 2)2.83 (2.31 to 3.46)2.55 (2.08 to 3.13)9.23 (7.21 to 12)2.34 (1.82 to 2.99)3.94 (3.11 to 4.98)2.40 (1.92 to 3.01)
M14459 strain (Month 3)18.29 (15 to 23)12.85 (10 to 16)5.30 (4.04 to 6.93)2.15 (1.64 to 2.82)3.11 (2.40 to 4.02)15.24 (12 to 20)
M14459 strain (Month 7)3.52 (2.91 to 4.26)3.24 (2.68 to 3.93)2.19 (1.74 to 2.77)27.47 (22 to 35)1.95 (1.56 to 2.43)28.56 (23 to 35)
M14459 strain (Month 13)2.46 (2.03 to 2.97)2.29 (1.89 to 2.78)1.95 (1.54 to 2.45)3.22 (2.55 to 4.06)29.01 (23 to 36)3.17 (2.57 to 3.92)
M07-0241084 strain (Month 0)2.26 (1.81 to 2.82)2.07 (1.65 to 2.59)2.01 (1.53 to 2.63)2.06 (1.57 to 2.71)2.59 (1.99 to 3.37)1.83 (1.42 to 2.36)
M07-0241084 strain (Month 2)5.09 (4.26 to 6.07)4.30 (3.59 to 5.14)6.73 (5.44 to 8.34)3.51 (2.83 to 4.35)4.90 (3.97 to 6.04)4.20 (3.43 to 5.15)
M07-0241084 strain(Month 3)13.91 (12 to 17)8.82 (7.29 to 11)4.39 (3.49 to 5.50)3.30 (2.62 to 4.15)3.55 (2.84 to 4.43)9.29 (7.49 to 12)
M07-0241084 strain (Month 7)5.42 (4.51 to 6.51)4.68 (3.88 to 5.63)3.36 (2.69 to 4.20)15.70 (13 to 20)2.96 (2.38 to 3.67)19.18 (16 to 24)
M07-0241084 strain(Month 13)4.45 (3.71 to 5.35)4.01 (3.34 to 4.83)3.07 (2.46 to 3.83)5.42 (4.33 to 6.77)15.68 (13 to 19)5.80 (4.70 to 7.16)
96217 strain (Month 0)2.32 (1.82 to 2.95)2.84 (2.23 to 3.62)2.88 (2.16 to 3.83)2.39 (1.78 to 3.21)2.78 (2.11 to 3.68)2.57 (1.94 to 3.40)
96217 strain(Month 2)16.48 (13 to 21)11.62 (8.96 to 15)124.75 (92 to 169)11.61 (8.49 to 16)11.94 (8.87 to 16)8.54 (6.33 to 12)
96217 strain(Month 3)263.56 (211 to 329)169.65 (136 to 212)82.23 (63 to 107)8.61 (6.57 to 11)7.72 (5.97 to 9.99)162.27 (125 to 210)
96217 strain (Month 7)61.46 (50 to 75)43.01 (35 to 53)37.26 (29 to 47)264.85 (207 to 340)5.19 (4.10 to 6.58)306.14 (242 to 388)
96217 strain (Month 13)33.07 (27 to 41)22.48 (18 to 28)24.00 (18 to 31)42.27 (32 to 55)264.32 (205 to 341)47.22 (37 to 61)
Serogroup A (Month 0)1.37 (1.18 to 1.59)1.17 (1.02 to 1.36)1.38 (1.15 to 1.65)1.08 (0.90 to 1.30)1.19 (1.00 to 1.41)1.06 (0.90 to 1.25)
Serogroup A (Month 2)4.05 (2.97 to 5.54)8.35 (6.14 to 11)85.49 (59 to 125)7.64 (5.22 to 11)22.54 (16 to 32)5.18 (3.65 to 7.34)
Serogroup A (Month 3)106.70 (82 to 139)68.85 (53 to 89)52.42 (38 to 72)5.31 (3.86 to 7.31)8.77 (6.49 to 12)78.30 (58 to 105)
Serogroup A (Month 7)14.15 (11 to 19)11.49 (8.71 to 15)9.88 (7.04 to 14)165.14 (117 to 233)3.25 (2.35 to 4.49)140.73 (103 to 193)
Serogroup A (Month 13)5.80 (4.30 to 7.82)4.64 (3.45 to 6.23)5.90 (4.11 to 8.46)15.20 (11 to 22)168.23 (119 to 238)13.32 (9.52 to 19)
Serogroup C (Month 0)3.46 (2.76 to 4.33)3.38 (2.71 to 4.23)3.87 (2.96 to 5.04)3.36 (2.56 to 4.40)3.80 (2.92 to 4.94)2.99 (2.32 to 3.87)
Serogroup C (Month 2)9.47 (7.18 to 13)31.56 (24 to 42)163.28 (118 to 227)37.24 (27 to 52)54.75 (40 to 76)40.29 (29 to 55)
Serogroup C (Month 3)41.25 (32 to 52)184.05 (145 to 234)119.71 (90 to 159)31.50 (24 to 42)41.15 (31 to 54)236.97 (180 to 312)
Serogroup C (Month 7)11.03 (8.81 to 14)80.70 (65 to 101)76.97 (59 to 100)260.57 (199 to 342)24.59 (19 to 32)476.44 (369 to 615)
Serogroup C (Month 13)8.45 (6.79 to 11)37.45 (30 to 47)38.42 (30 to 50)57.48 (44 to 75)303.63 (235 to 392)113.72 (89 to 146)
Serogroup W (Month 0)6.43 (4.46 to 9.27)4.75 (3.35 to 6.73)4.54 (2.98 to 6.90)4.29 (2.80 to 6.58)4.95 (3.30 to 7.44)4.46 (2.97 to 6.69)
Serogroup W (Month 2)17.43 (13 to 23)50.71 (39 to 66)175.57 (128 to 241)59.37 (43 to 82)94.34 (69 to 128)47.54 (35 to 65)
Serogroup W (Month 3)138.43 (111 to 173)214.70 (173 to 266)125.70 (97 to 162)59.26 (46 to 77)86.66 (68 to 111)200.91 (157 to 258)
Serogroup W (Month 7)22.53 (18 to 29)79.96 (63 to 101)74.84 (57 to 99)340.85 (256 to 453)58.19 (44 to 76)270.12 (206 to 354)
Serogroup W (Month 13)12.63 (9.86 to 16)45.63 (36 to 58)46.83 (35 to 62)96.43 (72 to 129)478.73 (363 to 631)95.90 (73 to 126)
Serogroup Y (Month 0)1.72 (1.41 to 2.10)1.40 (1.14 to 1.71)1.68 (1.32 to 2.13)1.24 (0.97 to 1.59)1.79 (1.42 to 2.25)1.34 (1.07 to 1.67)
Serogroup Y (Month 2)2.36 (1.72 to 3.23)19.43 (14 to 27)63.45 (44 to 93)16.41 (11 to 24)27.00 (19 to 39)19.82 (14 to 28)
Serogroup Y (Month 3)3.12 (2.34 to 4.17)90.61 (68 to 121)42.97 (30 to 61)15.95 (11 to 23)18.76 (13 to 26)97.12 (70 to 134)
Serogroup Y (Month 7)2.44 (1.87 to 3.17)34.27 (26 to 45)27.86 (20 to 38)152.73 (111 to 211)14.29 (11 to 19)180.33 (135 to 242)
Serogroup Y (Month 13)2.28 (1.75 to 2.96)18.13 (14 to 24)15.19 (11 to 21)42.14 (31 to 58)231.39 (171 to 313)53.78 (40 to 72)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against NZ98/254 B strain was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13.
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
NZ98/254 Strain (At Month 0) ≥ LLQ (8.2)7 (3.73 to 11.53)6 (3.40 to 11.06)6 (2.38 to 11.65)5 (1.99 to 11.30)4 (1.30 to 9.02)2 (0.46 to 6.40)
NZ98/254 Strain (At Month 0) ≥ 59 (4.94 to 13.45)7 (3.79 to 11.72)7 (2.92 to 12.71)5 (1.99 to 11.30)6 (2.26 to 11.11)3 (0.82 to 7.47)
NZ98/254 Strain (At Month 0) ≥ 87 (4.13 to 12.18)6 (3.40 to 11.06)6 (2.38 to 11.65)5 (1.99 to 11.30)4 (1.30 to 9.02)2 (0.46 to 6.40)
NZ98/254 Strain (At Month 0) ≥ 164 (1.85 to 8.21)5 (2.62 to 9.72)4 (1.37 to 9.46)4 (0.98 to 8.89)2 (0.19 to 5.62)1 (0.02 to 4.09)
NZ98/254 Strain (At Month 0) ≥ 322 (0.33 to 4.59)3 (0.88 to 6.19)3 (0.52 to 7.13)1 (0.02 to 4.87)0 (0 to 2.89)0 (0 to 2.72)
NZ98/254 Strain (At Month 0) ≥ 640 (0 to 1.94)3 (0.34 to 4.67)0 (0 to 3.03)1 (0.02 to 4.87)0 (0 to 2.89)0 (0 to 2.72)
NZ98/254 Strain (At Month 0) ≥ 1280 (0 to 1.94)0 (0 to 1.97)0 (0 to 3.03)0 (0 to 3.24)0 (0 to 2.89)0 (0 to 2.72)
NZ98/254 Strain (At Month 2) ≥ LLQ (8.2)23 (17.55 to 30.12)20 (14.49 to 26.50)43 (33.53 to 51.85)17 (10.53 to 25.22)27 (19.47 to 35.62)18 (11.83 to 25.47)
NZ98/254 Strain (At Month 2) ≥ 529 (22.86 to 36.32)24 (18.33 to 31.16)58 (48.98 to 67.26)18 (11.26 to 26.22)36 (27.38 to 44.74)20 (13.72 to 27.95)
NZ98/254 Strain (At Month 2) ≥ 823 (17.55 to 30.12)20 (14.49 to 26.50)43 (33.53 to 51.85)17 (10.53 to 25.22)28 (20.17 to 36.46)18 (11.83 to 25.47)
NZ98/254 Strain (At Month 2) ≥ 1619 (13.79 to 25.51)15 (10.30 to 21.13)28 (20.49 to 37.28)11 (5.66 to 17.97)23 (15.99 to 31.35)13 (7.57 to 19.53)
NZ98/254 Strain (At Month 2) ≥ 3215 (10.13 to 20.80)10 (5.87 to 14.94)20 (13.25 to 28.28)9 (4.36 to 15.81)17 (10.62 to 24.34)7 (3.64 to 13.30)
NZ98/254 Strain (At Month 2) ≥ 649 (4.94 to 13.45)7 (3.79 to 11.72)12 (6.53 to 18.80)4 (0.98 to 8.89)13 (7.44 to 19.80)2 (0.46 to 6.40)
NZ98/254 Strain (At Month 2) ≥ 1282 (0.33 to 4.59)5 (2.25 to 9.03)5 (1.86 to 10.57)3 (0.56 to 7.63)6 (2.78 to 12.13)1 (0.18 to 5.29)
NZ98/254 Strain (At Month 3) ≥ LLQ (8.2)88 (82.82 to 92.52)61 (53.65 to 68.15)30 (21.98 to 39.04)14 (8.39 to 22.16)20 (13.27 to 27.88)68 (59.30 to 75.71)
NZ98/254 Strain (At Month 3) ≥ 594 (89.12 to 96.66)76 (68.84 to 81.67)38 (29.61 to 47.65)17 (10.53 to 25.22)27 (19.47 to 35.62)78 (70.42 to 85.00)
NZ98/254 Strain (At Month 3) ≥ 888 (82.82 to 92.52)63 (55.30 to 69.69)30 (21.98 to 39.04)14 (8.39 to 22.16)21 (13.94 to 28.75)69 (60.86 to 77.07)
NZ98/254 Strain (At Month 3) ≥ 1674 (67.05 to 80.05)44 (37.04 to 51.79)18 (11.86 to 26.43)11 (5.66 to 17.97)14 (8.69 to 21.63)46 (37.62 to 55.08)
NZ98/254 Strain (At Month 3) ≥ 3250 (42.64 to 57.36)23 (17.36 to 30.00)13 (7.17 to 19.78)5 (1.99 to 11.30)10 (5.02 to 16.05)19 (12.45 to 26.30)
NZ98/254 Strain (At Month 3) ≥ 6429 (22.86 to 36.32)12 (7.60 to 17.45)6 (2.38 to 11.65)4 (0.98 to 8.89)6 (2.26 to 11.11)14 (8.76 to 21.25)
NZ98/254 Strain (At Month 3) ≥ 12812 (7.48 to 17.18)6 (3.40 to 11.06)4 (1.37 to 9.46)2 (0.22 to 6.30)4 (1.30 to 9.02)4 (1.66 to 9.49)
NZ98/254 Strain (At Month 7) ≥ LLQ (8.2)27 (20.43 to 33.52)19 (14.02 to 25.91)14 (8.47 to 21.71)63 (53.76 to 72.29)13 (7.44 to 19.80)72 (64.00 to 79.76)
NZ98/254 Strain (At Month 7) ≥ 533 (26.31 to 40.19)27 (20.77 to 34.03)18 (11.86 to 26.43)80 (71.78 to 87.26)17 (11.28 to 25.23)82 (74.53 to 88.17)
NZ98/254 Strain (At Month 7) ≥ 827 (20.43 to 33.52)20 (14.49 to 26.50)14 (8.47 to 21.71)69 (59.30 to 77.17)13 (7.44 to 19.80)74 (65.59 to 81.08)
NZ98/254 Strain (At Month 7) ≥ 1621 (15.19 to 27.25)14 (9.39 to 19.91)12 (6.53 to 18.80)46 (36.10 to 55.22)10 (5.02 to 16.05)55 (46.40 to 63.82)
NZ98/254 Strain (At Month 7) ≥ 3212 (7.92 to 17.79)10 (6.30 to 15.57)9 (4.67 to 15.81)26 (18.08 to 35.03)4 (1.30 to 9.02)34 (25.66 to 42.25)
NZ98/254 Strain (At Month 7) ≥ 646 (3.34 to 10.88)6 (3.40 to 11.06)6 (2.38 to 11.65)13 (7.69 to 21.13)2 (0.19 to 5.62)16 (10.58 to 23.80)
NZ98/254 Strain (At Month 7) ≥ 1282 (0.33 to 4.59)4 (1.53 to 7.64)5 (1.86 to 10.57)7 (3.13 to 13.59)1 (0.02 to 4.34)5 (2.13 to 10.47)
NZ98/254 Strain (At Month 13) ≥ LLQ (8.2)21 (15.19 to 27.25)16 (11.22 to 22.33)15 (9.14 to 22.67)18 (11.26 to 26.22)73 (64.38 to 80.53)19 (13.08 to 27.12)
NZ98/254 Strain (At Month 13) ≥ 527 (20.43 to 33.52)19 (14.02 to 25.91)16 (9.81 to 23.62)28 (19.64 to 36.93)85 (77.46 to 90.67)25 (17.60 to 32.81)
NZ98/254 Strain (At Month 13) ≥ 821 (15.19 to 27.25)16 (11.22 to 22.33)15 (9.14 to 22.67)18 (11.26 to 26.22)74 (65.23 to 81.24)19 (13.08 to 27.12)
NZ98/254 Strain (At Month 13) ≥ 1615 (10.13 to 20.80)12 (8.05 to 18.07)8 (4.07 to 14.79)12 (6.33 to 19.03)49 (40.19 to 58.26)14 (8.76 to 21.25)
NZ98/254 Strain (At Month 13) ≥ 327 (4.13 to 12.18)7 (3.79 to 11.72)8 (3.49 to 13.76)8 (3.74 to 14.71)30 (22.31 to 38.97)4 (1.66 to 9.49)
NZ98/254 Strain (At Month 13) ≥ 643 (0.87 to 6.10)5 (2.25 to 9.03)5 (1.86 to 10.57)5 (1.99 to 11.30)13 (8.06 to 20.72)3 (0.82 to 7.47)
NZ98/254 Strain (At Month 13) ≥ 1282 (0.33 to 4.59)3 (0.88 to 6.19)3 (0.92 to 8.31)3 (0.56 to 7.63)6 (2.78 to 12.13)2 (0.46 to 6.40)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M14459 B strain was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13.
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
M14459 Strain (At Month 0) ≥ LLQ (8.0)7 (3.41 to 11.11)5 (2.32 to 9.33)6 (2.55 to 12.45)4 (1.02 to 9.21)7 (2.85 to 12.41)2 (0.46 to 6.40)
M14459 Strain (At Month 0) ≥ 512 (7.65 to 17.54)7 (3.92 to 12.10)6 (2.55 to 12.45)6 (2.65 to 12.90)11 (6.36 to 18.36)4 (1.22 to 8.49)
M14459 Strain (At Month 0) ≥ 87 (3.41 to 11.11)5 (2.32 to 9.33)6 (2.55 to 12.45)4 (1.02 to 9.21)7 (2.85 to 12.41)2 (0.46 to 6.40)
M14459 Strain (At Month 0) ≥ 163 (0.89 to 6.23)2 (0.35 to 4.82)2 (0.22 to 6.30)3 (0.58 to 7.90)2 (0.51 to 6.96)1 (0.18 to 5.29)
M14459 Strain (At Month 0) ≥ 322 (0.34 to 4.69)0 (0 to 2.04)1 (0.02 to 4.87)1 (0.02 to 5.05)0 (0 to 2.95)1 (0.02 to 4.09)
M14459 Strain (At Month 0) ≥ 641 (0.13 to 3.87)0 (0 to 2.04)0 (0 to 3.24)0 (0 to 3.36)0 (0 to 2.95)1 (0.02 to 4.09)
M14459 Strain (At Month 0) ≥ 1280 (0 to 1.98)0 (0 to 2.04)0 (0 to 3.24)0 (0 to 3.36)0 (0 to 2.95)0 (0 to 2.72)
M14459 Strain (At Month 2) ≥ LLQ (8.0)28 (21.88 to 35.35)24 (17.96 to 30.96)61 (51.04 to 69.81)17 (10.19 to 25.06)34 (25.84 to 43.24)17 (11.20 to 24.63)
M14459 Strain (At Month 2) ≥ 538 (30.49 to 44.92)30 (23.03 to 36.88)75 (65.93 to 82.70)26 (17.97 to 35.25)42 (33.42 to 51.51)22 (15.64 to 30.39)
M14459 Strain (At Month 2) ≥ 828 (21.88 to 35.35)24 (17.96 to 30.96)61 (51.04 to 69.81)17 (10.19 to 25.06)34 (25.84 to 43.24)17 (11.20 to 24.63)
M14459 Strain (At Month 2) ≥ 1617 (11.74 to 23.05)13 (8.32 to 18.65)34 (25.25 to 43.48)11 (5.87 to 18.06)25 (17.81 to 33.83)12 (6.98 to 18.67)
M14459 Strain (At Month 2) ≥ 329 (5.05 to 13.74)6 (3.11 to 10.73)19 (12.00 to 27.22)6 (2.07 to 11.70)13 (7.62 to 20.26)5 (2.13 to 10.47)
M14459 Strain (At Month 2) ≥ 644 (1.90 to 8.39)2 (0.61 to 5.62)4 (0.98 to 8.89)2 (0.23 to 6.53)8 (3.97 to 14.44)2 (0.46 to 6.40)
M14459 Strain (At Month 2) ≥ 1281 (0.01 to 2.99)2 (0.35 to 4.82)2 (0.22 to 6.30)1 (0.02 to 5.05)5 (1.81 to 10.32)1 (0.18 to 5.29)
M14459 Strain (At Month 3) ≥ LLQ (8.0)82 (75.75 to 87.32)68 (60.21 to 74.39)44 (34.39 to 53.44)16 (9.45 to 24.00)28 (20.69 to 37.29)73 (64.80 to 80.42)
M14459 Strain (At Month 3) ≥ 584 (78.16 to 89.18)74 (66.66 to 80.03)54 (44.78 to 63.90)20 (13.23 to 29.20)35 (26.58 to 44.08)80 (72.05 to 86.28)
M14459 Strain (At Month 3) ≥ 882 (75.75 to 87.32)68 (60.21 to 74.39)44 (34.39 to 53.44)16 (9.45 to 24.00)28 (20.69 to 37.29)73 (64.80 to 80.42)
M14459 Strain (At Month 3) ≥ 1666 (58.98 to 73.09)51 (43.83 to 58.92)24 (16.53 to 33.10)9 (4.53 to 16.37)18 (11.56 to 25.82)51 (41.98 to 59.48)
M14459 Strain (At Month 3) ≥ 3239 (32.03 to 46.58)30 (23.54 to 37.46)6 (2.55 to 12.45)4 (1.02 to 9.21)9 (4.55 to 15.44)28 (20.91 to 36.79)
M14459 Strain (At Month 3) ≥ 6418 (12.68 to 24.25)11 (6.51 to 16.08)3 (0.56 to 7.63)1 (0.02 to 5.05)4 (1.33 to 9.23)10 (5.83 to 16.91)
M14459 Strain (At Month 3) ≥ 1287 (3.41 to 11.11)2 (0.61 to 5.62)2 (0.22 to 6.30)1 (0.02 to 5.05)3 (0.89 to 8.12)3 (0.82 to 7.47)
M14459 Strain (At Month 7) ≥ LLQ (8.0)34 (26.91 to 41.02)30 (23.03 to 36.88)17 (10.53 to 25.22)86 (78.13 to 92.01)15 (9.56 to 23.07)89 (82.21 to 93.60)
M14459 Strain (At Month 7) ≥ 544 (36.73 to 51.51)35 (28.22 to 42.67)21 (14.24 to 30.19)92 (84.77 to 96.12)20 (12.92 to 27.63)93 (87.63 to 96.88)
M14459 Strain (At Month 7) ≥ 834 (26.91 to 41.02)30 (23.03 to 36.88)17 (10.53 to 25.22)86 (78.13 to 92.01)15 (9.56 to 23.07)89 (82.21 to 93.60)
M14459 Strain (At Month 7) ≥ 1619 (13.62 to 25.45)14 (9.25 to 19.92)10 (5.01 to 16.89)69 (59.84 to 77.95)8 (3.97 to 14.44)72 (63.21 to 79.09)
M14459 Strain (At Month 7) ≥ 3211 (7.21 to 16.92)7 (3.51 to 11.42)5 (1.99 to 11.30)50 (40.22 to 59.78)6 (2.32 to 11.37)49 (40.52 to 58.02)
M14459 Strain (At Month 7) ≥ 643 (1.21 to 6.96)4 (1.59 to 7.89)3 (0.56 to 7.63)23 (15.57 to 32.25)4 (1.33 to 9.23)22 (15.64 to 30.39)
M14459 Strain (At Month 7) ≥ 1280 (0 to 1.98)1 (0.01 to 3.07)1 (0.02 to 4.87)10 (5.20 to 17.49)2 (0.20 to 5.75)7 (3.12 to 12.37)
M14459 Strain (At Month 13) ≥ LLQ (8.0)23 (17.46 to 30.16)20 (14.01 to 26.13)13 (7.01 to 20.08)23 (15.57 to 32.25)89 (81.64 to 93.64)27 (19.58 to 35.20)
M14459 Strain (At Month 13) ≥ 530 (23.88 to 37.63)26 (19.47 to 32.75)20 (12.74 to 28.22)37 (27.94 to 46.86)93 (86.56 to 96.60)38 (29.82 to 46.84)
M14459 Strain (At Month 13) ≥ 823 (17.46 to 30.16)20 (14.01 to 26.13)13 (7.01 to 20.08)23 (15.57 to 32.25)89 (81.64 to 93.64)27 (19.58 to 35.20)
M14459 Strain (At Month 13) ≥ 1615 (9.90 to 20.63)9 (5.63 to 14.77)7 (3.13 to 13.59)13 (7.27 to 20.79)76 (67.05 to 82.90)13 (7.57 to 19.53)
M14459 Strain (At Month 13) ≥ 325 (2.64 to 9.77)4 (1.95 to 8.62)4 (0.98 to 8.89)7 (3.25 to 14.07)54 (45.25 to 63.47)6 (2.61 to 11.42)
M14459 Strain (At Month 13) ≥ 642 (0.34 to 4.69)2 (0.61 to 5.62)3 (0.56 to 7.63)1 (0.02 to 5.05)29 (21.41 to 38.15)1 (0.18 to 5.29)
M14459 Strain (At Month 13) ≥ 1280 (0 to 1.98)1 (0.01 to 3.07)2 (0.22 to 6.30)1 (0.02 to 5.05)11 (5.75 to 17.40)1 (0.02 to 4.09)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M07-0241084 B strain was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13.
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
M07-0241084 Strain (At Month 0) ≥ LLQ (8.9)21 (15.19 to 27.25)18 (12.78 to 24.69)17 (10.77 to 25.16)14 (8.32 to 21.97)21 (14.54 to 29.88)19 (12.40 to 26.60)
M07-0241084 Strain (At Month 0) ≥ 530 (23.35 to 36.87)28 (21.36 to 35.08)25 (17.27 to 33.62)27 (19.46 to 36.63)30 (21.79 to 38.74)21 (14.38 to 29.19)
M07-0241084 Strain (At Month 0) ≥ 822 (16.13 to 28.40)20 (14.26 to 26.56)18 (11.47 to 26.12)19 (12.62 to 27.98)24 (16.68 to 32.57)20 (13.72 to 28.33)
M07-0241084 Strain (At Month 0) ≥ 1613 (8.79 to 19.00)14 (9.41 to 20.25)12 (6.70 to 19.26)6 (2.53 to 12.35)16 (9.73 to 23.43)15 (9.18 to 22.21)
M07-0241084 Strain (At Month 0) ≥ 328 (4.53 to 12.82)6 (3.16 to 10.91)7 (3.00 to 13.03)4 (0.97 to 8.82)9 (4.63 to 15.68)6 (2.74 to 11.94)
M07-0241084 Strain (At Month 0) ≥ 643 (1.18 to 6.82)2 (0.35 to 4.90)3 (0.53 to 7.31)2 (0.22 to 6.25)3 (0.91 to 8.25)3 (0.86 to 7.81)
M07-0241084 Strain (At Month 0) ≥ 1280 (0 to 1.94)0 (0 to 2.07)0 (0 to 3.10)2 (0.22 to 6.25)1 (0.02 to 4.52)1 (0.02 to 4.28)
M07-0241084 Strain (At Month 2) ≥ LLQ (8.9)38 (30.81 to 45.11)29 (22.40 to 36.28)37 (28.03 to 46.16)28 (20.24 to 37.57)39 (30.12 to 48.13)30 (22.65 to 39.22)
M07-0241084 Strain (At Month 2) ≥ 547 (40.03 to 54.74)43 (35.75 to 50.85)54 (44.39 to 63.10)40 (30.73 to 49.46)54 (44.43 to 62.83)41 (32.04 to 49.66)
M07-0241084 Strain (At Month 2) ≥ 842 (34.88 to 49.42)32 (25.54 to 39.84)43 (33.63 to 52.21)31 (22.61 to 40.36)43 (34.01 to 52.29)35 (26.93 to 44.09)
M07-0241084 Strain (At Month 2) ≥ 1631 (24.33 to 37.98)22 (16.26 to 29.02)29 (21.04 to 38.17)16 (9.72 to 24.00)30 (21.79 to 38.74)19 (12.40 to 26.60)
M07-0241084 Strain (At Month 2) ≥ 3220 (14.72 to 26.67)15 (10.36 to 21.53)17 (10.77 to 25.16)7 (3.11 to 13.47)19 (12.45 to 27.14)9 (4.37 to 14.86)
M07-0241084 Strain (At Month 2) ≥ 6410 (5.77 to 14.71)7 (3.99 to 12.30)9 (4.17 to 15.16)2 (0.22 to 6.25)9 (4.63 to 15.68)5 (1.74 to 9.92)
M07-0241084 Strain (At Month 2) ≥ 1283 (1.18 to 6.82)2 (0.35 to 4.90)3 (0.53 to 7.31)1 (0.02 to 4.83)5 (1.84 to 10.48)0 (0 to 2.84)
M07-0241084 Strain (At Month 3) ≥ LLQ (8.9)66 (59.26 to 73.19)47 (39.60 to 54.81)28 (20.28 to 37.27)28 (20.24 to 37.57)30 (21.79 to 38.74)53 (44.11 to 62.00)
M07-0241084 Strain (At Month 3) ≥ 579 (72.75 to 84.81)69 (61.94 to 76.04)43 (33.63 to 52.21)40 (30.73 to 49.46)43 (34.01 to 52.29)62 (52.72 to 70.17)
M07-0241084 Strain (At Month 3) ≥ 869 (62.02 to 75.67)55 (47.45 to 62.60)34 (25.67 to 43.53)31 (22.61 to 40.36)34 (25.53 to 43.05)56 (47.21 to 65.00)
M07-0241084 Strain (At Month 3) ≥ 1652 (44.74 to 59.45)33 (26.07 to 40.43)21 (14.33 to 29.91)12 (6.27 to 18.87)21 (14.54 to 29.88)40 (31.30 to 48.87)
M07-0241084 Strain (At Month 3) ≥ 3233 (26.31 to 40.19)18 (12.78 to 24.69)15 (9.38 to 23.22)5 (1.97 to 11.20)15 (9.06 to 22.49)23 (15.73 to 30.89)
M07-0241084 Strain (At Month 3) ≥ 6418 (12.40 to 23.76)11 (7.08 to 17.00)5 (1.90 to 10.83)1 (0.02 to 4.83)4 (1.36 to 9.38)13 (7.32 to 19.50)
M07-0241084 Strain (At Month 3) ≥ 1285 (2.21 to 8.89)3 (0.93 to 6.50)3 (0.53 to 7.31)1 (0.02 to 4.83)2 (0.51 to 7.07)2 (0.49 to 6.70)
M07-0241084 Strain (At Month 7) ≥ LLQ (8.9)40 (32.84 to 47.27)30 (22.92 to 36.88)26 (18.02 to 34.54)66 (56.88 to 74.99)26 (18.12 to 34.35)70 (61.60 to 78.06)
M07-0241084 Strain (At Month 7) ≥ 550 (42.64 to 57.36)44 (36.30 to 51.42)32 (24.11 to 41.76)83 (74.99 to 89.56)36 (27.81 to 45.60)80 (72.53 to 86.94)
M07-0241084 Strain (At Month 7) ≥ 842 (34.88 to 49.42)32 (25.54 to 39.84)27 (19.52 to 36.36)70 (60.57 to 78.18)28 (20.31 to 36.99)77 (68.26 to 83.59)
M07-0241084 Strain (At Month 7) ≥ 1629 (22.37 to 35.76)24 (18.28 to 31.47)19 (12.18 to 27.07)53 (43.48 to 62.55)18 (11.76 to 26.22)58 (48.77 to 66.49)
M07-0241084 Strain (At Month 7) ≥ 3221 (15.19 to 27.25)14 (8.94 to 19.61)9 (4.79 to 16.20)28 (20.24 to 37.57)8 (4.03 to 14.67)34 (25.49 to 42.48)
M07-0241084 Strain (At Month 7) ≥ 646 (2.96 to 10.23)8 (4.42 to 12.99)6 (2.44 to 11.94)10 (4.96 to 16.75)4 (1.36 to 9.38)17 (11.10 to 24.86)
M07-0241084 Strain (At Month 7) ≥ 1281 (0.01 to 2.93)2 (0.35 to 4.90)1 (0.02 to 4.67)3 (0.55 to 7.56)1 (0.02 to 4.52)4 (1.28 to 8.88)
M07-0241084 Strain (At Month 13) ≥ LLQ (8.9)34 (26.81 to 40.74)27 (20.84 to 34.48)23 (15.79 to 31.77)34 (25.01 to 43.12)69 (59.53 to 76.73)37 (28.38 to 45.69)
M07-0241084 Strain (At Month 13) ≥ 546 (38.48 to 53.15)39 (31.95 to 46.83)36 (27.24 to 45.29)57 (46.99 to 65.93)82 (73.78 to 88.24)51 (41.80 to 59.72)
M07-0241084 Strain (At Month 13) ≥ 837 (29.81 to 44.02)34 (26.60 to 41.01)27 (19.52 to 36.36)39 (29.91 to 48.56)74 (64.76 to 81.16)42 (33.51 to 51.23)
M07-0241084 Strain (At Month 13) ≥ 1626 (19.46 to 32.39)23 (16.76 to 29.64)17 (10.77 to 25.16)19 (12.62 to 27.98)55 (45.24 to 63.62)26 (18.46 to 34.26)
M07-0241084 Strain (At Month 13) ≥ 3216 (11.03 to 21.99)13 (8.47 to 18.96)11 (6.05 to 18.25)12 (6.27 to 18.87)35 (26.29 to 43.90)12 (6.71 to 18.59)
M07-0241084 Strain (At Month 13) ≥ 646 (3.34 to 10.88)3 (1.26 to 7.27)4 (1.40 to 9.69)5 (1.97 to 11.20)20 (13.14 to 28.06)5 (1.74 to 9.92)
M07-0241084 Strain (At Month 13) ≥ 1282 (0.58 to 5.36)1 (0.01 to 3.12)2 (0.21 to 6.04)1 (0.02 to 4.83)9 (4.63 to 15.68)1 (0.02 to 4.28)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against 96217 B strain was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13.
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
96217 Strain (At Month 0) ≥ LLQ (8.6)23 (17.26 to 29.85)29 (22.14 to 35.89)29 (21.23 to 38.16)28 (19.64 to 36.93)25 (17.77 to 33.42)27 (19.57 to 36.12)
96217 Strain (At Month 0) ≥ 526 (19.68 to 32.72)35 (28.38 to 42.90)35 (26.52 to 44.24)29 (21.23 to 38.82)35 (26.93 to 44.09)29 (21.05 to 37.87)
96217 Strain (At Month 0) ≥ 824 (18.23 to 31.00)30 (23.68 to 37.66)31 (22.73 to 39.91)28 (19.64 to 36.93)25 (17.77 to 33.42)27 (19.57 to 36.12)
96217 Strain (At Month 0) ≥ 1616 (11.15 to 22.22)17 (11.67 to 23.18)22 (14.67 to 30.11)19 (12.00 to 27.22)18 (11.74 to 25.73)16 (9.73 to 23.43)
96217 Strain (At Month 0) ≥ 326 (3.38 to 11.00)8 (4.37 to 12.84)8 (4.07 to 14.79)4 (1.47 to 10.11)8 (3.81 to 13.90)7 (2.90 to 12.61)
96217 Strain (At Month 0) ≥ 642 (0.33 to 4.64)2 (0.62 to 5.65)3 (0.52 to 7.13)0 (0 to 3.24)2 (0.49 to 6.70)5 (1.84 to 10.48)
96217 Strain (At Month 0) ≥ 1281 (0.01 to 2.96)1 (0.14 to 4.00)0 (0 to 3.03)0 (0 to 3.24)1 (0.02 to 4.28)2 (0.20 to 5.84)
96217 Strain (At Month 2) ≥ LLQ (8.6)69 (61.63 to 75.39)64 (56.53 to 71.09)97 (91.69 to 99.08)62 (51.94 to 70.64)58 (48.77 to 66.49)50 (40.37 to 58.82)
96217 Strain (At Month 2) ≥ 575 (68.42 to 81.29)67 (60.00 to 74.24)97 (91.69 to 99.08)66 (56.52 to 74.75)66 (56.72 to 73.79)53 (43.61 to 62.03)
96217 Strain (At Month 2) ≥ 870 (63.31 to 76.88)64 (56.53 to 71.09)97 (91.69 to 99.08)63 (53.76 to 72.29)59 (50.34 to 67.96)51 (41.99 to 60.43)
96217 Strain (At Month 2) ≥ 1648 (41.01 to 55.81)48 (40.78 to 55.91)94 (88.35 to 97.62)48 (38.67 to 57.85)42 (33.51 to 51.23)39 (30.12 to 48.13)
96217 Strain (At Month 2) ≥ 3227 (21.15 to 34.43)21 (15.57 to 28.10)84 (76.38 to 90.19)20 (12.74 to 28.22)26 (18.46 to 34.26)24 (16.68 to 32.57)
96217 Strain (At Month 2) ≥ 6411 (6.69 to 16.12)15 (9.77 to 20.67)73 (63.60 to 80.25)9 (4.36 to 15.81)14 (8.55 to 21.31)12 (6.47 to 18.65)
96217 Strain (At Month 2) ≥ 1287 (3.77 to 11.66)4 (1.96 to 8.66)45 (35.91 to 54.35)4 (1.47 to 10.11)9 (4.94 to 15.80)7 (3.46 to 13.65)
96217 Strain (At Month 3) ≥ LLQ (8.6)99 (97.04 to 99.99)97 (92.81 to 98.75)94 (88.35 to 97.62)58 (48.34 to 67.30)47 (38.00 to 55.89)97 (91.75 to 99.09)
96217 Strain (At Month 3) ≥ 599 (97.04 to 99.99)97 (93.57 to 99.08)96 (90.54 to 98.53)61 (51.04 to 69.81)56 (47.21 to 65.00)98 (92.93 to 99.49)
96217 Strain (At Month 3) ≥ 899 (97.04 to 99.99)97 (92.81 to 98.75)95 (89.43 to 98.14)58 (48.34 to 67.30)52 (43.34 to 61.24)97 (91.75 to 99.09)
96217 Strain (At Month 3) ≥ 1699 (97.04 to 99.99)95 (90.62 to 97.66)91 (84.19 to 95.33)40 (31.03 to 49.86)36 (27.65 to 44.89)95 (89.52 to 98.16)
96217 Strain (At Month 3) ≥ 3298 (95.36 to 99.67)89 (83.83 to 93.45)83 (75.44 to 89.51)21 (13.49 to 29.20)23 (15.73 to 30.89)92 (85.33 to 95.97)
96217 Strain (At Month 3) ≥ 6490 (84.51 to 93.74)81 (74.34 to 86.39)62 (52.35 to 70.39)6 (2.55 to 12.45)11 (6.11 to 17.67)84 (76.57 to 90.27)
96217 Strain (At Month 3) ≥ 12874 (67.28 to 80.32)63 (55.38 to 70.03)34 (25.76 to 43.38)4 (1.47 to 10.11)4 (1.28 to 8.88)60 (51.04 to 69.11)
96217 Strain (At Month 7) ≥ LLQ (8.6)95 (91.01 to 97.76)91 (85.81 to 94.77)88 (80.22 to 92.83)97 (92.37 to 99.44)39 (30.56 to 48.08)99 (95.48 to 99.98)
96217 Strain (At Month 7) ≥ 596 (92.40 to 98.47)93 (87.83 to 96.05)91 (84.19 to 95.33)97 (92.37 to 99.44)44 (35.00 to 52.79)99 (95.48 to 99.98)
96217 Strain (At Month 7) ≥ 895 (91.01 to 97.76)91 (85.81 to 94.77)88 (80.22 to 92.83)97 (92.37 to 99.44)40 (31.30 to 48.87)99 (95.48 to 99.98)
96217 Strain (At Month 7) ≥ 1693 (88.34 to 96.23)85 (79.33 to 90.23)76 (67.17 to 83.18)96 (91.11 to 99.02)30 (22.65 to 39.22)99 (95.48 to 99.98)
96217 Strain (At Month 7) ≥ 3275 (67.85 to 80.80)65 (57.68 to 72.14)57 (47.31 to 65.68)96 (89.89 to 98.53)18 (11.74 to 25.73)98 (94.16 to 99.80)
96217 Strain (At Month 7) ≥ 6443 (35.79 to 50.46)34 (26.81 to 41.16)32 (23.48 to 40.78)87 (78.87 to 92.31)7 (3.27 to 12.93)98 (92.93 to 99.49)
96217 Strain (At Month 7) ≥ 12811 (7.13 to 16.74)7 (3.53 to 11.48)12 (6.53 to 18.80)73 (64.02 to 81.14)2 (0.49 to 6.70)85 (77.51 to 90.94)
96217 Strain (At Month 13) ≥ LLQ (8.6)87 (81.41 to 91.55)83 (76.20 to 87.85)81 (72.64 to 87.44)90 (83.11 to 94.99)98 (93.30 to 99.51)93 (87.39 to 97.10)
96217 Strain (At Month 13) ≥ 590 (85.14 to 94.16)85 (78.70 to 89.76)83 (75.44 to 89.51)92 (85.29 to 96.26)98 (94.47 to 99.81)93 (87.39 to 97.10)
96217 Strain (At Month 13) ≥ 888 (82.03 to 92.00)83 (76.82 to 88.33)81 (72.64 to 87.44)90 (83.11 to 94.99)98 (94.47 to 99.81)93 (87.39 to 97.10)
96217 Strain (At Month 13) ≥ 1676 (69.00 to 81.77)69 (61.75 to 75.80)66 (56.62 to 74.24)79 (70.80 to 86.51)98 (93.30 to 99.51)88 (80.38 to 92.89)
96217 Strain (At Month 13) ≥ 3252 (44.72 to 59.51)40 (32.64 to 47.48)41 (31.95 to 50.18)57 (47.45 to 66.45)96 (91.12 to 98.72)64 (55.25 to 72.95)
96217 Strain (At Month 13) ≥ 6423 (17.26 to 29.85)13 (8.37 to 18.76)23 (15.38 to 31.02)30 (22.02 to 39.76)85 (77.79 to 90.82)36 (27.81 to 45.60)
96217 Strain (At Month 13) ≥ 1284 (1.87 to 8.30)3 (0.92 to 6.43)8 (3.49 to 13.76)13 (7.69 to 21.13)73 (64.08 to 80.16)12 (7.11 to 19.62)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against A human serogroup was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13.
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
A human Serogroup (At Month 0) ≥ LLQ (22.7)6 (2.82 to 10.43)3 (1.25 to 7.19)5 (1.53 to 10.57)2 (0.23 to 6.71)3 (0.52 to 7.13)1 (0.02 to 4.31)
A human Serogroup (At Month 0) ≥ 510 (6.32 to 16.03)6 (3.12 to 10.79)10 (5.24 to 17.65)4 (1.05 to 9.47)8 (3.49 to 13.76)3 (0.86 to 7.87)
A human Serogroup (At Month 0) ≥ 810 (5.86 to 15.35)6 (2.73 to 10.09)10 (5.24 to 17.65)3 (0.59 to 8.12)5 (1.86 to 10.57)2 (0.49 to 6.75)
A human Serogroup (At Month 0) ≥ 167 (3.66 to 11.87)4 (1.96 to 8.66)7 (3.28 to 14.20)2 (0.23 to 6.71)4 (1.37 to 9.46)2 (0.19 to 5.57)
A human Serogroup (At Month 0) ≥ 324 (1.65 to 8.21)2 (0.62 to 5.65)3 (0.58 to 7.98)1 (0.02 to 5.19)2 (0.20 to 5.89)1 (0.02 to 4.31)
A human Serogroup (At Month 0) ≥ 641 (0.14 to 4.14)1 (0.14 to 4.00)2 (0.23 to 6.59)1 (0.02 to 5.19)0 (0 to 3.03)1 (0.02 to 4.31)
A human Serogroup (At Month 0) ≥ 1281 (0.01 to 3.20)1 (0.01 to 3.09)1 (0.02 to 5.10)0 (0 to 3.45)0 (0 to 3.03)1 (0.02 to 4.31)
A human Serogroup (At Month 2) ≥ LLQ (22.7)22 (16.13 to 29.04)35 (27.86 to 42.32)93 (85.80 to 96.72)33 (24.43 to 43.20)54 (44.83 to 63.29)28 (20.01 to 36.19)
A human Serogroup (At Month 2) ≥ 537 (29.97 to 44.89)53 (45.76 to 60.87)95 (89.43 to 98.47)48 (37.78 to 57.59)75 (66.27 to 82.45)39 (30.08 to 47.63)
A human Serogroup (At Month 2) ≥ 837 (29.43 to 44.30)51 (42.98 to 58.12)94 (88.19 to 97.91)46 (35.96 to 55.72)74 (65.38 to 81.72)38 (29.35 to 46.83)
A human Serogroup (At Month 2) ≥ 1628 (21.35 to 35.24)44 (36.41 to 51.44)93 (86.98 to 97.33)41 (31.45 to 50.98)67 (57.48 to 75.01)31 (22.83 to 39.51)
A human Serogroup (At Month 2) ≥ 3219 (13.09 to 25.24)33 (26.28 to 40.58)88 (80.12 to 93.37)30 (21.02 to 39.22)42 (32.74 to 51.02)22 (15.18 to 30.26)
A human Serogroup (At Month 2) ≥ 6412 (7.72 to 18.06)19 (13.12 to 25.04)69 (59.50 to 77.73)18 (11.26 to 26.81)33 (24.23 to 41.65)14 (8.62 to 21.47)
A human Serogroup (At Month 2) ≥ 1284 (1.65 to 8.21)10 (5.66 to 14.85)34 (24.80 to 43.42)9 (3.99 to 15.65)14 (8.47 to 21.71)6 (2.76 to 12.03)
A human Serogroup (At Month 3) ≥ LLQ (22.7)94 (89.57 to 97.18)87 (80.61 to 91.17)80 (71.58 to 87.42)30 (21.02 to 39.22)38 (28.83 to 46.80)92 (86.00 to 96.16)
A human Serogroup (At Month 3) ≥ 597 (93.35 to 99.05)94 (89.21 to 96.88)92 (84.63 to 96.08)40 (30.56 to 50.02)55 (45.65 to 64.09)94 (88.97 to 97.76)
A human Serogroup (At Month 3) ≥ 897 (93.35 to 99.05)93 (87.83 to 96.05)91 (83.48 to 95.43)39 (29.67 to 49.06)53 (43.18 to 61.69)94 (87.97 to 97.24)
A human Serogroup (At Month 3) ≥ 1695 (90.30 to 97.58)91 (85.81 to 94.77)86 (77.93 to 91.94)33 (24.43 to 43.20)42 (32.74 to 51.02)92 (86.00 to 96.16)
A human Serogroup (At Month 3) ≥ 3291 (85.33 to 94.59)83 (76.20 to 87.85)74 (64.45 to 81.85)27 (18.51 to 36.19)31 (22.73 to 39.91)90 (83.13 to 94.44)
A human Serogroup (At Month 3) ≥ 6471 (63.53 to 77.59)57 (49.69 to 64.67)46 (36.12 to 55.70)12 (6.76 to 20.24)19 (12.56 to 27.36)61 (51.57 to 69.18)
A human Serogroup (At Month 3) ≥ 12845 (37.76 to 53.10)30 (23.17 to 37.07)21 (14.14 to 30.49)6 (2.13 to 12.02)10 (5.27 to 16.82)29 (21.41 to 37.85)
A human Serogroup (At Month 7) ≥ LLQ (22.7)53 (45.74 to 61.12)46 (38.04 to 53.12)41 (31.70 to 51.05)95 (89.24 to 98.44)21 (13.96 to 29.20)94 (87.97 to 97.24)
A human Serogroup (At Month 7) ≥ 570 (62.31 to 76.53)62 (54.80 to 69.50)60 (49.89 to 69.18)97 (91.88 to 99.41)29 (21.23 to 38.16)98 (93.25 to 99.51)
A human Serogroup (At Month 7) ≥ 868 (60.50 to 74.92)58 (50.82 to 65.75)58 (48.01 to 67.42)97 (91.88 to 99.41)28 (19.75 to 36.40)98 (93.25 to 99.51)
A human Serogroup (At Month 7) ≥ 1661 (53.33 to 68.38)51 (43.53 to 58.67)49 (38.82 to 58.46)97 (91.88 to 99.41)22 (14.67 to 30.11)97 (92.13 to 99.14)
A human Serogroup (At Month 7) ≥ 3242 (34.95 to 50.20)37 (29.44 to 44.05)35 (25.65 to 44.39)91 (84.35 to 96.01)14 (8.47 to 21.71)93 (86.97 to 96.71)
A human Serogroup (At Month 7) ≥ 6419 (13.59 to 25.88)19 (13.61 to 25.66)18 (11.04 to 26.33)76 (66.89 to 83.96)7 (2.92 to 12.71)80 (72.33 to 86.84)
A human Serogroup (At Month 7) ≥ 1285 (2.42 to 9.70)6 (2.73 to 10.09)10 (5.24 to 17.65)63 (52.88 to 72.09)3 (0.52 to 7.13)54 (44.48 to 62.44)
A human Serogroup (At Month 13) ≥ LLQ (22.7)33 (26.16 to 40.71)26 (20.09 to 33.52)34 (24.80 to 43.42)51 (41.47 to 61.30)93 (87.29 to 97.08)54 (45.26 to 63.19)
A human Serogroup (At Month 13) ≥ 551 (42.87 to 58.28)42 (34.25 to 49.18)48 (37.92 to 57.54)68 (57.79 to 76.43)98 (92.87 to 99.48)65 (55.59 to 72.85)
A human Serogroup (At Month 13) ≥ 848 (40.59 to 55.99)39 (31.57 to 46.34)47 (37.02 to 56.62)66 (55.81 to 74.70)98 (92.87 to 99.48)64 (54.78 to 72.12)
A human Serogroup (At Month 13) ≥ 1638 (30.52 to 45.49)30 (23.68 to 37.66)41 (31.70 to 51.05)59 (49.02 to 68.55)95 (89.43 to 98.14)60 (50.78 to 68.44)
A human Serogroup (At Month 13) ≥ 3224 (17.68 to 30.92)20 (14.09 to 26.27)27 (18.96 to 36.55)44 (34.14 to 53.83)88 (81.20 to 93.47)41 (32.30 to 50.02)
A human Serogroup (At Month 13) ≥ 6413 (8.67 to 19.39)8 (4.79 to 13.52)13 (7.34 to 20.98)27 (18.51 to 36.19)81 (72.64 to 87.44)16 (9.89 to 23.27)
A human Serogroup (At Month 13) ≥ 1284 (1.65 to 8.21)2 (0.35 to 4.85)6 (2.09 to 11.81)8 (3.35 to 14.46)61 (51.50 to 69.61)6 (2.24 to 11.03)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against C human serogroup was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13.
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
C human Serogroup (At Month 0) ≥ LLQ (5.2)43 (35.79 to 50.46)45 (38.09 to 52.87)48 (38.43 to 56.78)41 (32.09 to 50.83)48 (38.88 to 57.16)41 (32.24 to 49.73)
C human Serogroup (At Month 0) ≥ 546 (38.91 to 53.68)45 (38.09 to 52.87)49 (40.02 to 58.38)43 (33.75 to 52.59)49 (39.67 to 57.95)42 (32.97 to 50.51)
C human Serogroup (At Month 0) ≥ 834 (27.61 to 41.71)30 (23.75 to 37.44)36 (27.57 to 45.25)30 (21.62 to 39.11)36 (27.33 to 44.91)30 (22.28 to 38.66)
C human Serogroup (At Month 0) ≥ 1619 (13.47 to 25.19)14 (8.94 to 19.30)20 (13.03 to 27.84)14 (8.24 to 21.79)24 (17.10 to 32.95)8 (3.75 to 13.69)
C human Serogroup (At Month 0) ≥ 325 (2.61 to 9.66)6 (3.40 to 11.06)9 (4.59 to 15.56)4 (0.96 to 8.74)7 (3.40 to 13.44)3 (0.84 to 7.69)
C human Serogroup (At Month 0) ≥ 642 (0.59 to 5.41)2 (0.34 to 4.67)2 (0.20 to 5.80)3 (0.55 to 7.50)3 (0.89 to 8.12)1 (0.02 to 4.21)
C human Serogroup (At Month 0) ≥ 1281 (0.01 to 2.96)2 (0.34 to 4.67)0 (0 to 2.98)1 (0.02 to 4.79)1 (0.02 to 4.45)0 (0 to 2.80)
C human Serogroup (At Month 2) ≥ LLQ (5.2)61 (53.89 to 68.33)84 (78.27 to 89.24)100 (97.02 to 100)84 (76.20 to 90.37)89 (82.60 to 94.25)88 (80.78 to 92.80)
C human Serogroup (At Month 2) ≥ 562 (54.98 to 69.35)84 (78.27 to 89.24)100 (97.02 to 100)84 (76.20 to 90.37)89 (82.60 to 94.25)88 (80.78 to 92.80)
C human Serogroup (At Month 2) ≥ 853 (45.25 to 60.04)78 (71.16 to 83.60)98 (94.20 to 99.80)80 (71.28 to 86.76)86 (78.80 to 91.74)78 (69.56 to 84.52)
C human Serogroup (At Month 2) ≥ 1635 (28.62 to 42.82)65 (57.52 to 71.73)95 (89.60 to 98.17)64 (54.51 to 72.81)72 (62.71 to 79.31)61 (51.82 to 69.21)
C human Serogroup (At Month 2) ≥ 3218 (13.00 to 24.60)40 (32.88 to 47.44)89 (81.50 to 93.58)44 (34.58 to 53.46)55 (46.06 to 64.25)44 (35.16 to 52.82)
C human Serogroup (At Month 2) ≥ 648 (4.58 to 12.95)23 (17.36 to 30.00)79 (70.35 to 85.58)29 (20.84 to 38.19)39 (30.36 to 48.23)25 (17.49 to 32.94)
C human Serogroup (At Month 2) ≥ 1283 (0.88 to 6.16)16 (10.76 to 21.73)53 (44.03 to 62.36)17 (10.34 to 24.80)26 (18.52 to 34.70)19 (12.85 to 27.07)
C human Serogroup (At Month 3) ≥ LLQ (5.2)97 (93.84 to 99.12)99 (96.15 to 99.87)98 (94.20 to 99.80)81 (72.25 to 87.49)88 (80.68 to 93.01)99 (95.79 to 99.98)
C human Serogroup (At Month 3) ≥ 597 (93.84 to 99.12)99 (96.15 to 99.87)98 (94.20 to 99.80)81 (72.25 to 87.49)88 (80.68 to 93.01)100 (97.20 to 100)
C human Serogroup (At Month 3) ≥ 894 (89.00 to 96.62)98 (94.56 to 99.41)98 (92.98 to 99.49)77 (68.40 to 84.53)84 (76.01 to 89.78)99 (95.79 to 99.98)
C human Serogroup (At Month 3) ≥ 1678 (71.89 to 84.17)96 (92.36 to 98.47)95 (89.60 to 98.17)62 (52.72 to 71.19)63 (54.25 to 71.91)98 (93.40 to 99.52)
C human Serogroup (At Month 3) ≥ 3256 (48.46 to 63.17)90 (84.43 to 93.70)86 (78.63 to 91.67)43 (33.75 to 52.59)46 (36.53 to 54.75)94 (88.23 to 97.31)
C human Serogroup (At Month 3) ≥ 6426 (19.68 to 32.72)78 (71.16 to 83.60)67 (58.13 to 75.44)25 (17.75 to 34.45)30 (22.14 to 39.00)85 (77.24 to 90.34)
C human Serogroup (At Month 3) ≥ 12811 (6.69 to 16.12)58 (50.92 to 65.57)40 (31.39 to 49.42)18 (11.06 to 25.79)21 (14.30 to 29.42)60 (51.05 to 68.49)
C human Serogroup (At Month 7) ≥ LLQ (5.2)69 (61.63 to 75.39)96 (92.36 to 98.47)97 (91.82 to 99.10)99 (95.21 to 99.98)82 (74.18 to 88.44)100 (97.20 to 100)
C human Serogroup (At Month 7) ≥ 569 (62.19 to 75.89)96 (92.36 to 98.47)97 (91.82 to 99.10)99 (95.21 to 99.98)82 (74.18 to 88.44)100 (97.20 to 100)
C human Serogroup (At Month 7) ≥ 858 (50.62 to 65.24)96 (92.36 to 98.47)96 (90.69 to 98.66)99 (95.21 to 99.98)73 (64.43 to 80.76)99 (95.79 to 99.98)
C human Serogroup (At Month 7) ≥ 1638 (30.65 to 45.02)90 (85.06 to 94.13)91 (84.44 to 95.41)98 (93.81 to 99.79)55 (46.06 to 64.25)99 (95.79 to 99.98)
C human Serogroup (At Month 7) ≥ 3223 (16.79 to 29.27)74 (66.54 to 79.72)77 (68.57 to 84.18)95 (88.90 to 98.04)35 (26.58 to 44.08)98 (94.55 to 99.81)
C human Serogroup (At Month 7) ≥ 649 (5.00 to 13.59)53 (45.51 to 60.34)53 (44.03 to 62.36)86 (78.21 to 91.76)26 (18.52 to 34.70)96 (91.25 to 98.74)
C human Serogroup (At Month 7) ≥ 1283 (0.88 to 6.16)30 (23.75 to 37.44)25 (17.96 to 34.09)74 (64.61 to 81.49)16 (10.22 to 23.99)85 (78.12 to 90.97)
C human Serogroup (At Month 13) ≥ LLQ (5.2)60 (52.25 to 66.79)92 (87.63 to 95.80)94 (88.54 to 97.66)97 (92.50 to 99.45)100 (97.05 to 100)99 (95.79 to 99.98)
C human Serogroup (At Month 13) ≥ 561 (53.34 to 67.82)92 (87.63 to 95.80)94 (88.54 to 97.66)98 (93.81 to 99.79)100 (97.05 to 100)99 (95.79 to 99.98)
C human Serogroup (At Month 13) ≥ 848 (41.01 to 55.81)88 (82.55 to 92.40)89 (82.47 to 94.20)91 (84.46 to 95.71)98 (94.25 to 99.80)98 (93.40 to 99.52)
C human Serogroup (At Month 13) ≥ 1630 (23.61 to 37.25)78 (71.26 to 83.60)79 (70.35 to 85.58)83 (75.20 to 89.66)98 (93.04 to 99.49)94 (88.23 to 97.31)
C human Serogroup (At Month 13) ≥ 3215 (10.24 to 21.02)51 (43.37 to 58.22)57 (48.10 to 66.28)61 (51.83 to 70.37)97 (91.88 to 99.11)81 (72.93 to 87.15)
C human Serogroup (At Month 13) ≥ 649 (5.00 to 13.59)28 (21.76 to 35.17)25 (17.25 to 33.21)38 (28.81 to 47.28)93 (87.59 to 97.15)58 (49.49 to 67.03)
C human Serogroup (At Month 13) ≥ 1282 (0.59 to 5.41)16 (10.76 to 21.73)16 (10.31 to 24.18)25 (16.98 to 33.51)85 (76.93 to 90.44)40 (31.51 to 48.95)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against W human serogroup was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13.
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
W human Serogroup (At Month 0) ≥ LLQ (39.6)30 (23.29 to 37.95)26 (19.86 to 33.17)29 (21.42 to 38.46)20 (13.23 to 29.20)29 (21.41 to 38.15)22 (14.99 to 30.31)
W human Serogroup (At Month 0) ≥ 551 (43.27 to 59.15)43 (35.98 to 50.91)41 (32.24 to 50.57)42 (32.25 to 51.55)45 (35.75 to 53.94)45 (35.75 to 53.94)
W human Serogroup (At Month 0) ≥ 849 (41.45 to 57.34)41 (33.85 to 48.67)40 (31.45 to 49.72)41 (31.38 to 50.62)45 (35.75 to 53.94)43 (34.20 to 52.32)
W human Serogroup (At Month 0) ≥ 1644 (36.05 to 51.83)39 (31.73 to 46.42)39 (30.66 to 48.87)34 (25.40 to 44.01)41 (31.89 to 49.88)38 (29.60 to 47.41)
W human Serogroup (At Month 0) ≥ 3235 (27.86 to 43.07)31 (24.43 to 38.42)31 (22.93 to 40.23)24 (16.37 to 33.25)33 (25.09 to 42.40)26 (18.52 to 34.70)
W human Serogroup (At Month 0) ≥ 6421 (14.99 to 28.07)19 (13.45 to 25.38)20 (13.37 to 28.51)13 (7.27 to 20.79)21 (14.30 to 29.42)12 (6.99 to 19.32)
W human Serogroup (At Month 0) ≥ 1288 (4.34 to 13.33)9 (5.17 to 14.03)10 (5.32 to 16.95)10 (5.20 to 17.49)7 (2.85 to 12.41)4 (1.33 to 9.23)
W human Serogroup (At Month 2) ≥ LLQ (39.6)48 (40.24 to 56.12)65 (57.55 to 71.95)96 (90.47 to 98.62)67 (56.95 to 75.45)77 (68.81 to 84.31)60 (50.95 to 68.88)
W human Serogroup (At Month 2) ≥ 566 (58.21 to 73.29)90 (84.66 to 93.96)99 (95.41 to 99.98)92 (84.77 to 96.12)93 (86.56 to 96.60)93 (86.56 to 96.60)
W human Serogroup (At Month 2) ≥ 864 (56.30 to 71.57)86 (80.18 to 90.81)99 (95.41 to 99.98)92 (84.77 to 96.12)93 (86.56 to 96.60)89 (81.64 to 93.64)
W human Serogroup (At Month 2) ≥ 1660 (52.52 to 68.07)82 (75.84 to 87.51)99 (95.41 to 99.98)81 (72.86 to 88.31)89 (82.60 to 94.25)80 (72.37 to 87.08)
W human Serogroup (At Month 2) ≥ 3252 (44.49 to 60.36)69 (62.16 to 76.08)98 (94.06 to 99.80)72 (62.78 to 80.41)78 (69.69 to 85.01)65 (55.92 to 73.42)
W human Serogroup (At Month 2) ≥ 6444 (36.05 to 51.83)50 (42.47 to 57.53)84 (76.19 to 90.10)52 (42.03 to 61.57)67 (58.45 to 75.65)44 (34.97 to 53.13)
W human Serogroup (At Month 2) ≥ 12829 (22.16 to 36.65)31 (23.92 to 37.84)62 (52.84 to 70.91)33 (24.55 to 43.05)49 (39.67 to 57.95)27 (19.24 to 35.57)
W human Serogroup (At Month 3) ≥ LLQ (39.6)89 (83.01 to 93.28)97 (92.89 to 98.77)85 (77.15 to 90.78)68 (57.91 to 76.28)77 (68.81 to 84.31)97 (91.88 to 99.11)
W human Serogroup (At Month 3) ≥ 596 (92.11 to 98.63)99 (96.04 to 99.87)98 (94.06 to 99.80)94 (87.10 to 97.35)92 (85.56 to 96.03)100 (97.05 to 100)
W human Serogroup (At Month 3) ≥ 896 (92.11 to 98.63)99 (96.04 to 99.87)97 (92.81 to 99.48)90 (82.51 to 94.80)90 (83.58 to 94.86)100 (97.05 to 100)
W human Serogroup (At Month 3) ≥ 1696 (91.30 to 98.25)99 (96.04 to 99.87)96 (90.47 to 98.62)81 (71.83 to 87.54)86 (78.80 to 91.74)99 (95.55 to 99.98)
W human Serogroup (At Month 3) ≥ 3291 (85.19 to 94.72)98 (94.41 to 99.39)91 (84.06 to 95.29)73 (63.76 to 81.22)78 (69.69 to 85.01)98 (93.04 to 99.49)
W human Serogroup (At Month 3) ≥ 6480 (73.27 to 86.08)93 (88.64 to 96.51)77 (68.73 to 84.48)50 (40.22 to 59.78)64 (55.09 to 72.67)91 (84.56 to 95.45)
W human Serogroup (At Month 3) ≥ 12861 (53.15 to 68.66)74 (66.83 to 80.14)50 (41.11 to 59.71)33 (24.55 to 43.05)44 (34.97 to 53.13)70 (61.00 to 77.86)
W human Serogroup (At Month 7) ≥ LLQ (39.6)60 (51.90 to 67.49)82 (75.23 to 87.03)79 (70.57 to 85.92)99 (94.95 to 99.98)74 (65.30 to 81.48)99 (95.55 to 99.98)
W human Serogroup (At Month 7) ≥ 571 (63.35 to 77.84)97 (92.89 to 98.77)96 (90.47 to 98.62)100 (96.64 to 100)93 (86.56 to 96.60)100 (97.05 to 100)
W human Serogroup (At Month 7) ≥ 870 (62.70 to 77.28)95 (90.72 to 97.69)95 (89.35 to 98.13)100 (96.64 to 100)91 (84.56 to 95.45)100 (97.05 to 100)
W human Serogroup (At Month 7) ≥ 1669 (61.41 to 76.15)92 (87.29 to 95.68)91 (84.06 to 95.29)100 (96.64 to 100)87 (79.74 to 92.38)100 (97.05 to 100)
W human Serogroup (At Month 7) ≥ 3263 (55.03 to 70.41)84 (78.31 to 89.41)84 (76.19 to 90.10)100 (96.64 to 100)76 (67.93 to 83.61)99 (95.55 to 99.98)
W human Serogroup (At Month 7) ≥ 6449 (40.85 to 56.73)68 (60.42 to 74.54)67 (58.02 to 75.55)97 (92.10 to 99.42)59 (49.31 to 67.35)98 (93.04 to 99.49)
W human Serogroup (At Month 7) ≥ 12831 (23.85 to 38.59)41 (33.31 to 48.11)34 (25.98 to 43.72)87 (79.21 to 92.73)34 (25.84 to 43.24)82 (74.18 to 88.44)
W human Serogroup (At Month 13) ≥ LLQ (39.6)47 (39.04 to 54.90)64 (56.41 to 70.90)66 (56.28 to 74.02)82 (73.90 to 89.06)98 (93.04 to 99.49)84 (76.01 to 89.78)
W human Serogroup (At Month 13) ≥ 562 (54.40 to 69.83)93 (87.97 to 96.10)90 (83.05 to 94.68)99 (94.95 to 99.98)99 (95.55 to 99.98)98 (94.25 to 99.80)
W human Serogroup (At Month 13) ≥ 860 (52.52 to 68.07)90 (84.66 to 93.96)90 (83.05 to 94.68)98 (93.47 to 99.77)99 (95.55 to 99.98)98 (94.25 to 99.80)
W human Serogroup (At Month 13) ≥ 1657 (48.79 to 64.54)84 (77.69 to 88.94)81 (72.42 to 87.34)94 (87.10 to 97.35)99 (95.55 to 99.98)96 (90.77 to 98.67)
W human Serogroup (At Month 13) ≥ 3250 (42.05 to 57.95)71 (63.90 to 77.61)72 (63.32 to 80.08)85 (77.06 to 91.29)98 (94.25 to 99.80)89 (82.60 to 94.25)
W human Serogroup (At Month 13) ≥ 6435 (27.28 to 42.43)44 (36.52 to 51.47)48 (38.66 to 57.25)73 (63.76 to 81.22)98 (93.04 to 99.49)68 (59.29 to 76.39)
W human Serogroup (At Month 13) ≥ 12821 (14.99 to 28.07)22 (16.38 to 29.01)28 (19.92 to 36.68)43 (33.13 to 52.47)94 (88.63 to 97.68)45 (35.75 to 53.94)
SecondaryPercentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules.

The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against Y human serogroup was assessed.

Time frame:
At Month 0, Month 2, Month 3, Month 7 and Month 13.
Reported as:
Number · Percentages of subjects
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Y human Serogroup (At Month 0) ≥ LLQ (14.7)15 (10.13 to 20.80)10 (6.04 to 15.34)13 (7.82 to 20.75)6 (2.60 to 12.67)13 (7.38 to 19.65)7 (3.05 to 12.10)
Y human Serogroup (At Month 0) ≥ 516 (11.03 to 21.99)11 (6.92 to 16.64)15 (9.14 to 22.67)7 (3.19 to 13.83)17 (10.54 to 24.16)9 (4.61 to 14.80)
Y human Serogroup (At Month 0) ≥ 816 (11.03 to 21.99)11 (6.92 to 16.64)14 (8.47 to 21.71)7 (3.19 to 13.83)16 (9.89 to 23.27)9 (4.61 to 14.80)
Y human Serogroup (At Month 0) ≥ 1615 (10.13 to 20.80)10 (6.04 to 15.34)13 (7.17 to 19.78)6 (2.60 to 12.67)12 (6.76 to 18.73)6 (2.55 to 11.18)
Y human Serogroup (At Month 0) ≥ 329 (5.36 to 14.08)3 (0.91 to 6.36)8 (4.07 to 14.79)3 (0.57 to 7.76)8 (3.84 to 14.00)4 (1.62 to 9.29)
Y human Serogroup (At Month 0) ≥ 642 (0.58 to 5.36)2 (0.35 to 4.79)4 (1.37 to 9.46)0 (0 to 3.30)5 (1.75 to 10.00)3 (0.80 to 7.31)
Y human Serogroup (At Month 0) ≥ 1280 (0 to 1.94)1 (0.01 to 3.06)1 (0.02 to 4.56)0 (0 to 3.30)1 (0.02 to 4.31)1 (0.02 to 4.00)
Y human Serogroup (At Month 2) ≥ LLQ (14.7)21 (15.19 to 27.25)66 (58.70 to 72.99)85 (77.33 to 90.86)60 (50.22 to 69.22)72 (62.98 to 79.29)61 (52.62 to 69.51)
Y human Serogroup (At Month 2) ≥ 527 (20.91 to 34.08)72 (64.48 to 78.12)90 (83.18 to 94.73)65 (55.79 to 74.26)78 (69.74 to 84.82)65 (56.35 to 72.91)
Y human Serogroup (At Month 2) ≥ 826 (19.95 to 32.95)70 (62.74 to 76.59)89 (82.19 to 94.10)62 (52.07 to 70.92)76 (68.03 to 83.46)64 (54.85 to 71.56)
Y human Serogroup (At Month 2) ≥ 1620 (14.72 to 26.67)64 (56.41 to 70.90)85 (77.33 to 90.86)58 (48.39 to 67.52)69 (60.49 to 77.17)60 (51.14 to 68.13)
Y human Serogroup (At Month 2) ≥ 3213 (8.35 to 18.40)47 (39.75 to 54.79)75 (66.27 to 82.45)47 (37.68 to 57.02)54 (44.48 to 62.44)50 (41.70 to 59.01)
Y human Serogroup (At Month 2) ≥ 645 (2.21 to 8.89)31 (23.92 to 37.84)59 (49.82 to 68.05)30 (21.63 to 39.48)39 (30.08 to 47.63)39 (31.18 to 48.12)
Y human Serogroup (At Month 2) ≥ 1281 (0.13 to 3.79)14 (9.19 to 19.82)39 (30.39 to 48.50)12 (6.45 to 19.36)23 (15.86 to 31.12)23 (16.56 to 31.34)
Y human Serogroup (At Month 3) ≥ LLQ (14.7)27 (20.43 to 33.52)92 (87.29 to 95.68)80 (71.72 to 86.75)58 (48.39 to 67.52)62 (53.17 to 70.65)90 (83.45 to 94.30)
Y human Serogroup (At Month 3) ≥ 533 (26.31 to 40.19)94 (89.33 to 96.91)84 (76.38 to 90.19)65 (54.85 to 73.43)70 (61.32 to 77.88)93 (86.99 to 96.44)
Y human Serogroup (At Month 3) ≥ 830 (23.84 to 37.43)93 (88.64 to 96.51)83 (75.44 to 89.51)60 (50.22 to 69.22)67 (58.03 to 75.02)93 (86.99 to 96.44)
Y human Serogroup (At Month 3) ≥ 1626 (19.95 to 32.95)92 (86.63 to 95.26)79 (70.80 to 86.04)57 (47.48 to 66.66)59 (49.98 to 67.70)90 (83.45 to 94.30)
Y human Serogroup (At Month 3) ≥ 3218 (12.86 to 24.34)84 (77.69 to 88.94)68 (58.35 to 75.77)44 (34.20 to 53.42)44 (35.30 to 53.17)83 (75.88 to 89.05)
Y human Serogroup (At Month 3) ≥ 649 (4.94 to 13.45)68 (61.00 to 75.05)47 (37.51 to 55.99)24 (16.06 to 32.68)31 (23.55 to 40.33)65 (56.35 to 72.91)
Y human Serogroup (At Month 3) ≥ 1282 (0.58 to 5.36)39 (32.25 to 46.99)28 (19.75 to 36.40)16 (10.00 to 24.62)23 (15.86 to 31.12)47 (38.15 to 55.43)
Y human Serogroup (At Month 7) ≥ LLQ (14.7)23 (17.07 to 29.55)78 (70.99 to 83.62)72 (62.72 to 79.51)95 (88.51 to 97.97)54 (44.48 to 62.44)97 (92.69 to 99.20)
Y human Serogroup (At Month 7) ≥ 526 (19.95 to 32.95)86 (79.56 to 90.34)80 (71.72 to 86.75)95 (89.71 to 98.51)69 (59.67 to 76.45)99 (94.83 to 99.82)
Y human Serogroup (At Month 7) ≥ 826 (19.46 to 32.39)84 (77.69 to 88.94)77 (68.07 to 83.90)95 (89.71 to 98.51)64 (54.78 to 72.12)98 (93.73 to 99.55)
Y human Serogroup (At Month 7) ≥ 1622 (16.13 to 28.40)74 (66.83 to 80.14)69 (60.09 to 77.27)94 (87.33 to 97.40)52 (42.93 to 60.91)97 (92.69 to 99.20)
Y human Serogroup (At Month 7) ≥ 3213 (8.35 to 18.40)63 (55.27 to 69.85)54 (44.83 to 63.29)87 (79.57 to 92.86)40 (31.56 to 49.22)91 (85.20 to 95.39)
Y human Serogroup (At Month 7) ≥ 643 (0.87 to 6.10)37 (30.15 to 44.73)35 (26.52 to 44.24)79 (70.30 to 86.26)27 (19.31 to 35.35)75 (67.08 to 82.16)
Y human Serogroup (At Month 7) ≥ 1281 (0.01 to 2.93)14 (9.66 to 20.44)22 (14.67 to 30.11)57 (47.48 to 66.66)13 (8.00 to 20.56)57 (48.20 to 65.36)
Y human Serogroup (At Month 13) ≥ LLQ (14.7)19 (13.32 to 24.93)64 (56.41 to 70.90)58 (48.15 to 66.47)78 (69.30 to 85.49)97 (92.13 to 99.14)82 (75.06 to 88.44)
Y human Serogroup (At Month 13) ≥ 525 (18.98 to 31.82)76 (68.61 to 81.64)73 (64.49 to 80.99)91 (83.92 to 95.55)97 (92.13 to 99.14)91 (85.20 to 95.39)
Y human Serogroup (At Month 13) ≥ 824 (18.03 to 30.69)71 (63.90 to 77.61)63 (54.05 to 71.94)84 (75.38 to 90.00)97 (92.13 to 99.14)87 (80.03 to 92.02)
Y human Serogroup (At Month 13) ≥ 1618 (12.40 to 23.76)61 (53.58 to 68.27)55 (45.65 to 64.09)76 (67.32 to 83.94)97 (92.13 to 99.14)81 (73.44 to 87.21)
Y human Serogroup (At Month 13) ≥ 3210 (5.77 to 14.71)43 (35.45 to 50.35)40 (31.17 to 49.34)60 (50.22 to 69.22)93 (86.97 to 96.71)69 (60.13 to 76.27)
Y human Serogroup (At Month 13) ≥ 643 (1.18 to 6.82)21 (15.39 to 27.81)23 (15.38 to 31.02)41 (31.63 to 50.69)92 (86.00 to 96.16)46 (37.44 to 54.70)
Y human Serogroup (At Month 13) ≥ 1281 (0.13 to 3.79)9 (5.17 to 14.03)11 (5.90 to 17.81)21 (13.74 to 29.70)73 (64.65 to 80.69)28 (21.09 to 36.80)
SecondaryPercentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules.

The kinetic of immune response (at Months 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with two-, three- and four-fold titer rise against serogroups A, C, W and Y and serogroup B test strains was assessed. The two/three/four fold titer rise is defined as: a) for subjects with prevaccination hSBA titers ≤ LLQ, a postvaccination hSBA ≥ 2/3/4 LLQ; b) for subjects with a prevaccination hSBA titers ≥ LLQ, an increase of at least 2/3/4 times of the prevaccination hSBA titer.

Time frame:
At Month 2, Month 3, Month 7 and Month 13
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules.
Percentages of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
NZ98/254 Strain ≥ 2-fold (At Month 2)18 (12.86 to 24.34)13 (8.49 to 18.69)28 (19.75 to 36.40)9 (4.36 to 15.81)21 (14.62 to 29.62)12 (6.98 to 18.67)
NZ98/254 Strain ≥ 3-fold (At Month 2)14 (9.24 to 19.60)9 (5.44 to 14.30)19 (12.56 to 27.36)9 (4.36 to 15.81)17 (11.28 to 25.23)7 (3.64 to 13.30)
NZ98/254 Strain ≥ 4-fold (At Month 2)11 (7.05 to 16.57)8 (4.61 to 13.02)17 (10.49 to 24.56)7 (3.13 to 13.59)17 (10.62 to 24.34)7 (3.12 to 12.37)
NZ98/254 Strain ≥ 2-fold (At Month 3)73 (66.48 to 79.57)42 (34.43 to 49.08)18 (11.17 to 25.50)9 (4.36 to 15.81)13 (8.06 to 20.72)43 (34.76 to 52.11)
NZ98/254 Strain ≥ 3-fold (At Month 3)61 (53.81 to 68.18)32 (25.25 to 39.13)13 (7.17 to 19.78)5 (1.99 to 11.30)10 (5.61 to 17.00)28 (20.91 to 36.79)
NZ98/254 Strain ≥ 4-fold (At Month 3)47 (39.51 to 54.21)22 (15.92 to 28.26)9 (4.67 to 15.81)4 (0.98 to 8.89)9 (4.44 to 15.08)19 (12.45 to 26.30)
NZ98/254 Strain ≥ 2-fold (At Month 7)19 (13.32 to 24.93)12 (8.05 to 18.07)11 (5.90 to 17.81)45 (35.24 to 54.33)7 (3.32 to 13.13)54 (44.92 to 62.38)
NZ98/254 Strain ≥ 3-fold (At Month 7)11 (7.05 to 16.57)10 (6.30 to 15.57)7 (2.92 to 12.71)33 (24.44 to 42.56)6 (2.78 to 12.13)43 (34.76 to 52.11)
NZ98/254 Strain ≥ 4-fold (At Month 7)9 (5.36 to 14.08)8 (4.61 to 13.02)6 (2.38 to 11.65)24 (16.53 to 33.10)4 (1.30 to 9.02)33 (24.97 to 41.47)
NZ98/254 Strain ≥ 2-fold (At Month 13)11 (6.62 to 15.95)9 (5.44 to 14.30)7 (2.92 to 12.71)10 (5.01 to 16.89)49 (40.19 to 58.26)14 (8.76 to 21.25)
NZ98/254 Strain ≥ 3-fold (At Month 13)5 (2.58 to 9.56)7 (3.79 to 11.72)6 (2.38 to 11.65)9 (4.36 to 15.81)37 (28.12 to 45.55)7 (3.64 to 13.30)
NZ98/254 Strain ≥ 4-fold (At Month 13)4 (1.85 to 8.21)5 (2.62 to 9.72)5 (1.86 to 10.57)6 (2.55 to 12.45)26 (18.76 to 34.77)4 (1.66 to 9.49)
M14459 Strain ≥ 2-fold (At Month 2)14 (9.44 to 20.02)13 (8.32 to 18.65)34 (25.25 to 43.48)8 (3.88 to 15.23)23 (15.69 to 31.19)11 (6.40 to 17.79)
M14459 Strain ≥ 3-fold (At Month 2)10 (5.90 to 15.02)10 (6.07 to 15.43)23 (15.76 to 32.14)6 (2.07 to 11.70)15 (9.56 to 23.07)6 (2.61 to 11.42)
M14459 Strain ≥ 4-fold (At Month 2)7 (3.82 to 11.78)6 (2.71 to 10.03)15 (9.10 to 23.19)4 (1.02 to 9.21)12 (6.99 to 19.32)4 (1.22 to 8.49)
M14459 Strain ≥ 2-fold (At Month 3)65 (57.86 to 72.07)50 (42.72 to 57.82)24 (16.53 to 33.10)6 (2.65 to 12.90)14 (8.26 to 21.20)50 (41.25 to 58.75)
M14459 Strain ≥ 3-fold (At Month 3)49 (41.49 to 56.37)39 (31.38 to 46.10)10 (5.01 to 16.89)3 (0.58 to 7.90)11 (5.75 to 17.40)39 (30.52 to 47.60)
M14459 Strain ≥ 4-fold (At Month 3)38 (30.49 to 44.92)28 (22.01 to 35.70)4 (1.47 to 10.11)3 (0.58 to 7.90)7 (3.40 to 13.44)28 (20.24 to 36.00)
M14459 Strain ≥ 2-fold (At Month 7)16 (11.28 to 22.45)14 (9.25 to 19.92)9 (4.36 to 15.81)69 (58.88 to 77.12)7 (2.85 to 12.41)72 (63.21 to 79.09)
M14459 Strain ≥ 3-fold (At Month 7)12 (7.65 to 17.54)7 (3.92 to 12.10)6 (2.55 to 12.45)55 (44.76 to 64.24)6 (2.32 to 11.37)54 (45.65 to 63.10)
M14459 Strain ≥ 4-fold (At Month 7)8 (4.22 to 12.44)6 (3.11 to 10.73)4 (0.98 to 8.89)48 (38.43 to 57.97)5 (1.81 to 10.32)49 (39.79 to 57.29)
M14459 Strain ≥ 2-fold (At Month 13)11 (7.21 to 16.92)9 (5.63 to 14.77)6 (2.55 to 12.45)10 (5.20 to 17.49)74 (65.30 to 81.48)12 (6.98 to 18.67)
M14459 Strain ≥ 3-fold (At Month 13)8 (4.22 to 12.44)4 (1.95 to 8.62)4 (1.47 to 10.11)7 (3.25 to 14.07)59 (50.12 to 68.11)6 (2.61 to 11.42)
M14459 Strain ≥ 4-fold (At Month 13)3 (1.21 to 6.96)4 (1.59 to 7.89)3 (0.56 to 7.63)6 (2.07 to 11.70)51 (42.05 to 60.33)4 (1.66 to 9.49)
M07-0241084 Strain ≥ 2-fold (At Month 2)16 (11.49 to 22.58)11 (6.63 to 16.34)20 (12.89 to 28.02)5 (1.97 to 11.20)19 (12.45 to 27.14)8 (3.81 to 13.90)
M07-0241084 Strain ≥ 3-fold (At Month 2)12 (7.92 to 17.79)7 (3.57 to 11.61)9 (4.79 to 16.20)2 (0.22 to 6.25)12 (6.47 to 18.65)4 (1.28 to 8.88)
M07-0241084 Strain ≥ 4-fold (At Month 2)8 (4.53 to 12.82)5 (1.98 to 8.76)7 (3.00 to 13.03)2 (0.22 to 6.25)9 (4.63 to 15.68)1 (0.02 to 4.28)
M07-0241084 Strain ≥ 2-fold (At Month 3)37 (29.81 to 44.02)22 (16.26 to 29.02)11 (6.05 to 18.25)2 (0.22 to 6.25)8 (4.03 to 14.67)21 (14.38 to 29.19)
M07-0241084 Strain ≥ 3-fold (At Month 3)28 (21.40 to 34.64)12 (7.54 to 17.66)7 (3.00 to 13.03)1 (0.02 to 4.83)5 (1.84 to 10.48)17 (11.10 to 24.86)
M07-0241084 Strain ≥ 4-fold (At Month 3)19 (13.32 to 24.93)9 (5.29 to 14.34)4 (1.40 to 9.69)0 (0 to 3.21)4 (1.36 to 9.38)13 (7.93 to 20.41)
M07-0241084 Strain ≥ 2-fold (At Month 7)19 (13.32 to 24.93)13 (8.00 to 18.31)8 (3.58 to 14.10)43 (34.07 to 53.01)4 (1.36 to 9.38)42 (33.51 to 51.23)
M07-0241084 Strain ≥ 3-fold (At Month 7)11 (7.05 to 16.57)7 (3.99 to 12.30)6 (2.44 to 11.94)31 (22.61 to 40.36)1 (0.02 to 4.52)32 (24.06 to 40.85)
M07-0241084 Strain ≥ 4-fold (At Month 7)7 (4.13 to 12.18)6 (2.76 to 10.20)3 (0.94 to 8.52)19 (12.62 to 27.98)1 (0.02 to 4.52)22 (15.05 to 30.04)
M07-0241084 Strain ≥ 2-fold (At Month 13)13 (8.35 to 18.40)11 (7.08 to 17.00)8 (3.58 to 14.10)13 (7.62 to 20.95)41 (32.45 to 50.63)15 (9.18 to 22.21)
M07-0241084 Strain ≥ 3-fold (At Month 13)9 (4.94 to 13.45)7 (3.99 to 12.30)5 (1.90 to 10.83)9 (4.33 to 15.67)34 (25.53 to 43.05)10 (5.52 to 16.74)
M07-0241084 Strain ≥ 4-fold (At Month 13)5 (2.58 to 9.56)6 (2.76 to 10.20)4 (1.40 to 9.69)6 (2.53 to 12.35)21 (13.84 to 28.97)6 (2.74 to 11.94)
96217 Strain ≥ 2-fold (At Month 2)34 (27.61 to 41.71)29 (22.65 to 36.48)88 (81.20 to 93.47)32 (23.63 to 41.63)31 (23.35 to 40.04)26 (18.84 to 35.24)
96217 Strain ≥ 3-fold (At Month 2)26 (19.68 to 32.72)20 (14.09 to 26.27)81 (72.64 to 87.44)19 (12.00 to 27.22)18 (11.74 to 25.73)19 (12.45 to 27.14)
96217 Strain ≥ 4-fold (At Month 2)18 (12.54 to 24.00)13 (8.37 to 18.76)76 (67.17 to 83.18)12 (6.33 to 19.03)14 (8.55 to 21.31)16 (9.73 to 23.43)
96217 Strain ≥ 2-fold (At Month 3)97 (93.84 to 99.12)92 (87.16 to 95.63)85 (77.33 to 90.86)28 (19.64 to 36.93)23 (16.41 to 31.74)91 (84.32 to 95.37)
96217 Strain ≥ 3-fold (At Month 3)96 (92.40 to 98.47)89 (83.18 to 93.00)76 (67.17 to 83.18)14 (8.39 to 22.16)17 (11.10 to 24.86)88 (81.35 to 93.53)
96217 Strain ≥ 4-fold (At Month 3)94 (89.66 to 97.01)83 (76.20 to 87.85)69 (60.09 to 77.27)11 (5.66 to 17.97)13 (7.93 to 20.41)83 (75.63 to 89.60)
96217 Strain ≥ 2-fold (At Month 7)81 (74.81 to 86.53)74 (66.48 to 79.91)64 (54.90 to 72.71)96 (91.11 to 99.02)16 (10.45 to 23.98)97 (91.75 to 99.09)
96217 Strain ≥ 3-fold (At Month 7)73 (65.57 to 78.85)63 (55.38 to 70.03)52 (42.37 to 60.88)96 (91.11 to 99.02)9 (4.94 to 15.80)96 (90.62 to 98.64)
96217 Strain ≥ 4-fold (At Month 7)61 (53.89 to 68.33)50 (42.43 to 57.57)42 (32.74 to 51.02)95 (88.70 to 98.01)7 (3.27 to 12.93)94 (88.44 to 97.64)
96217 Strain ≥ 2-fold (At Month 13)65 (57.73 to 71.88)54 (46.32 to 61.42)52 (42.37 to 60.88)72 (63.07 to 80.36)96 (91.12 to 98.72)77 (68.32 to 84.04)
96217 Strain ≥ 3-fold (At Month 13)53 (45.78 to 60.56)39 (32.10 to 46.91)34 (25.76 to 43.38)54 (44.78 to 63.90)95 (89.06 to 97.77)62 (52.71 to 70.65)
96217 Strain ≥ 4-fold (At Month 13)35 (28.62 to 42.82)22 (16.57 to 29.32)28 (19.75 to 36.40)45 (35.24 to 54.33)93 (87.07 to 96.73)51 (41.99 to 60.43)
A human Serogroup ≥ 2-fold (At Month 2)12 (7.72 to 18.06)23 (17.07 to 29.92)78 (68.49 to 85.07)21 (13.62 to 29.99)38 (28.83 to 46.80)17 (10.54 to 24.16)
A human Serogroup ≥ 3-fold (At Month 2)9 (5.41 to 14.67)16 (11.19 to 22.55)64 (53.69 to 72.64)14 (8.22 to 22.47)30 (21.98 to 39.04)13 (7.38 to 19.65)
A human Serogroup ≥ 4-fold (At Month 2)6 (2.82 to 10.43)11 (6.55 to 16.17)50 (39.72 to 59.37)11 (6.05 to 19.11)20 (13.25 to 28.28)7 (3.29 to 13.03)
A human Serogroup ≥ 2-fold (At Month 3)80 (72.85 to 85.40)71 (63.52 to 77.35)61 (50.84 to 70.05)20 (12.83 to 28.93)24 (16.82 to 32.83)74 (65.49 to 81.39)
A human Serogroup ≥ 3-fold (At Month 3)66 (58.09 to 72.76)52 (44.64 to 59.77)41 (31.70 to 51.05)12 (6.76 to 20.24)18 (11.86 to 26.43)56 (46.83 to 64.70)
A human Serogroup ≥ 4-fold (At Month 3)56 (48.64 to 63.93)42 (34.79 to 49.75)31 (22.27 to 40.50)7 (2.72 to 13.25)14 (8.47 to 21.71)40 (31.56 to 49.22)
A human Serogroup ≥ 2-fold (At Month 7)27 (20.82 to 34.63)28 (21.11 to 34.71)25 (17.33 to 34.55)87 (78.64 to 92.51)8 (3.49 to 13.76)88 (81.27 to 93.24)
A human Serogroup ≥ 3-fold (At Month 7)17 (11.59 to 23.31)16 (11.19 to 22.55)16 (9.54 to 24.21)76 (66.89 to 83.96)6 (2.38 to 11.65)77 (68.88 to 84.14)
A human Serogroup ≥ 4-fold (At Month 7)11 (6.78 to 16.71)10 (5.66 to 14.85)13 (7.34 to 20.98)70 (60.78 to 78.98)5 (1.86 to 10.57)70 (61.32 to 77.88)
A human Serogroup ≥ 2-fold (At Month 13)16 (10.61 to 22.01)12 (7.91 to 18.11)18 (11.04 to 26.33)31 (22.72 to 41.22)85 (77.33 to 90.86)28 (20.71 to 37.02)
A human Serogroup ≥ 3-fold (At Month 13)9 (5.41 to 14.67)8 (4.37 to 12.84)11 (5.93 to 18.77)25 (16.86 to 34.14)80 (71.72 to 86.75)15 (9.25 to 22.37)
A human Serogroup ≥ 4-fold (At Month 13)5 (2.42 to 9.70)4 (1.60 to 7.93)9 (4.57 to 16.52)15 (8.97 to 23.56)78 (68.98 to 84.62)7 (3.29 to 13.03)
C human Serogroup ≥ 2-fold (At Month 2)24 (18.23 to 31.00)64 (56.41 to 70.71)95 (89.60 to 98.17)55 (45.66 to 64.58)73 (64.43 to 80.76)62 (52.61 to 69.93)
C human Serogroup ≥ 3-fold (At Month 2)15 (10.24 to 21.02)50 (42.84 to 57.69)91 (84.44 to 95.41)48 (38.79 to 57.80)59 (49.31 to 67.35)54 (44.89 to 62.62)
C human Serogroup ≥ 4-fold (At Month 2)9 (5.00 to 13.59)42 (34.43 to 49.08)88 (80.53 to 92.95)44 (34.58 to 53.46)50 (40.46 to 58.75)42 (32.97 to 50.51)
C human Serogroup ≥ 2-fold (At Month 3)80 (73.05 to 85.12)94 (89.61 to 96.99)93 (86.46 to 96.57)58 (48.29 to 67.08)65 (55.92 to 73.42)98 (93.40 to 99.52)
C human Serogroup ≥ 3-fold (At Month 3)64 (56.63 to 70.87)90 (85.06 to 94.13)90 (83.45 to 94.81)47 (37.94 to 56.94)50 (40.46 to 58.75)96 (91.25 to 98.74)
C human Serogroup ≥ 4-fold (At Month 3)49 (41.54 to 56.34)87 (81.31 to 91.51)83 (74.90 to 89.02)41 (32.09 to 50.83)42 (33.42 to 51.51)92 (85.36 to 95.70)
C human Serogroup ≥ 2-fold (At Month 7)29 (22.62 to 36.12)86 (80.70 to 91.06)89 (81.50 to 93.58)97 (92.50 to 99.45)50 (40.46 to 58.75)98 (94.55 to 99.81)
C human Serogroup ≥ 3-fold (At Month 7)16 (10.70 to 21.62)80 (73.50 to 85.51)79 (70.35 to 85.58)94 (87.76 to 97.50)37 (28.09 to 45.75)98 (94.55 to 99.81)
C human Serogroup ≥ 4-fold (At Month 7)10 (6.26 to 15.49)71 (64.26 to 77.75)72 (63.29 to 79.87)92 (85.54 to 96.33)28 (19.96 to 36.43)98 (93.40 to 99.52)
C human Serogroup ≥ 2-fold (At Month 13)19 (13.94 to 25.77)73 (65.97 to 79.23)74 (65.04 to 81.32)82 (73.23 to 88.22)97 (91.88 to 99.11)92 (86.31 to 96.25)
C human Serogroup ≥ 3-fold (At Month 13)13 (8.89 to 19.20)64 (56.41 to 70.71)61 (52.24 to 70.14)70 (60.89 to 78.38)96 (90.77 to 98.67)89 (82.59 to 93.99)
C human Serogroup ≥ 4-fold (At Month 13)10 (5.84 to 14.86)51 (43.91 to 58.75)53 (44.03 to 62.36)56 (46.54 to 65.42)93 (87.59 to 97.15)85 (77.24 to 90.34)
W human Serogroup ≥ 2-fold (At Month 2)24 (17.71 to 31.41)32 (24.95 to 39.00)65 (55.42 to 73.24)35 (26.24 to 44.96)50 (41.25 to 59.54)33 (25.09 to 42.40)
W human Serogroup ≥ 3-fold (At Month 2)17 (11.28 to 23.31)19 (13.93 to 25.99)52 (42.75 to 61.34)25 (17.17 to 34.25)40 (31.12 to 49.05)22 (14.99 to 30.31)
W human Serogroup ≥ 4-fold (At Month 2)11 (6.72 to 16.99)16 (11.06 to 22.31)42 (33.03 to 51.41)18 (10.94 to 26.10)34 (25.84 to 43.24)18 (11.56 to 25.82)
W human Serogroup ≥ 2-fold (At Month 3)67 (59.48 to 74.44)78 (71.59 to 84.12)55 (46.07 to 64.57)34 (25.40 to 44.01)46 (37.31 to 55.56)76 (67.93 to 83.61)
W human Serogroup ≥ 3-fold (At Month 3)54 (46.32 to 62.16)65 (57.55 to 71.95)39 (29.87 to 48.02)23 (15.57 to 32.25)34 (25.84 to 43.24)67 (58.45 to 75.65)
W human Serogroup ≥ 4-fold (At Month 3)43 (34.87 to 50.59)57 (49.09 to 64.02)30 (22.17 to 39.35)19 (12.46 to 28.17)28 (20.69 to 37.29)56 (46.87 to 65.03)
W human Serogroup ≥ 2-fold (At Month 7)31 (24.42 to 39.23)51 (43.57 to 58.62)43 (33.83 to 52.25)90 (82.51 to 94.80)41 (31.89 to 49.88)89 (81.64 to 93.64)
W human Serogroup ≥ 3-fold (At Month 7)22 (15.53 to 28.74)30 (23.41 to 37.26)29 (20.67 to 37.57)81 (71.83 to 87.54)28 (19.96 to 36.43)80 (72.37 to 87.08)
W human Serogroup ≥ 4-fold (At Month 7)13 (8.21 to 19.13)21 (14.91 to 27.20)17 (10.58 to 24.76)73 (63.76 to 81.22)20 (13.61 to 28.52)73 (64.43 to 80.76)
W human Serogroup ≥ 2-fold (At Month 13)20 (13.92 to 26.73)26 (19.36 to 32.58)32 (23.69 to 41.10)56 (46.60 to 66.00)94 (88.63 to 97.68)61 (51.77 to 69.64)
W human Serogroup ≥ 3-fold (At Month 13)9 (4.81 to 14.07)13 (8.28 to 18.55)17 (10.58 to 24.76)38 (28.80 to 47.81)92 (85.56 to 96.03)46 (36.53 to 54.75)
W human Serogroup ≥ 4-fold (At Month 13)7 (3.44 to 11.82)11 (6.48 to 15.99)13 (7.88 to 20.91)27 (18.78 to 36.24)89 (82.60 to 94.25)29 (21.41 to 38.15)
Y human Serogroup ≥ 2-fold (At Month 2)6 (2.96 to 10.23)49 (41.38 to 56.43)74 (65.38 to 81.72)47 (37.68 to 57.02)53 (43.70 to 61.68)51 (42.42 to 59.73)
Y human Serogroup ≥ 3-fold (At Month 2)4 (1.51 to 7.52)39 (32.25 to 46.99)64 (54.90 to 72.71)40 (30.78 to 49.78)41 (32.30 to 50.02)43 (34.64 to 51.80)
Y human Serogroup ≥ 4-fold (At Month 2)2 (0.58 to 5.36)32 (25.46 to 39.58)58 (48.15 to 66.47)33 (24.08 to 42.33)36 (27.88 to 45.22)37 (29.13 to 45.89)
Y human Serogroup ≥ 2-fold (At Month 3)10 (5.77 to 14.71)84 (78.31 to 89.41)66 (56.62 to 74.24)45 (35.93 to 55.23)46 (36.81 to 54.74)83 (75.88 to 89.05)
Y human Serogroup ≥ 3-fold (At Month 3)7 (3.73 to 11.53)80 (73.40 to 85.58)55 (45.65 to 64.09)35 (25.74 to 44.21)35 (26.43 to 43.60)75 (67.08 to 82.16)
Y human Serogroup ≥ 4-fold (At Month 3)4 (1.85 to 8.21)68 (61.00 to 75.05)48 (39.12 to 57.63)29 (20.82 to 38.52)31 (23.55 to 40.33)66 (57.86 to 74.26)
Y human Serogroup ≥ 2-fold (At Month 7)5 (2.21 to 8.89)60 (52.45 to 67.22)51 (41.55 to 60.07)90 (82.81 to 94.90)39 (30.08 to 47.63)92 (86.09 to 95.92)
Y human Serogroup ≥ 3-fold (At Month 7)3 (1.18 to 6.82)48 (40.29 to 55.34)44 (35.11 to 53.52)83 (74.35 to 89.27)28 (20.71 to 37.02)87 (80.03 to 92.02)
Y human Serogroup ≥ 4-fold (At Month 7)3 (0.87 to 6.10)41 (33.31 to 48.11)38 (29.61 to 47.65)79 (70.30 to 86.26)23 (15.86 to 31.12)76 (67.87 to 82.80)
Y human Serogroup ≥ 2-fold (At Month 13)5 (2.21 to 8.89)43 (35.45 to 50.35)38 (29.61 to 47.65)60 (50.22 to 69.22)94 (88.97 to 97.76)72 (63.20 to 78.91)
Y human Serogroup ≥ 3-fold (At Month 13)3 (1.18 to 6.82)34 (27.01 to 41.30)28 (20.49 to 37.28)48 (38.55 to 57.91)91 (84.08 to 95.02)54 (45.30 to 62.56)
Y human Serogroup ≥ 4-fold (At Month 13)2 (0.58 to 5.36)25 (18.86 to 31.99)23 (16.10 to 31.93)45 (35.93 to 55.23)89 (82.20 to 93.84)47 (38.15 to 55.43)
SecondaryThe Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains.

The area under the curve for percentage of subjects with hSBA titers ≥ LLQ for all serogroups (A, C, W and Y) and for all serogroup B test strains (M14459, 96217, NZ98/254 and M07-0241084) was summarized overall (from Month 0 to Month 13) and by period (from Month 0 to Month 2, Month 2 to Month 3, Month 3 to Month 7 and Month 7 to Month 13) by vaccine groups. It was computed as the sum of the trapezoidal areas and the time unit used was the month. AUC 0_13 = (r0+r2)(2-0)/2 + (r2+r3)(3-2)/2 + (r3+r7)(7-3)/2 + (r7+r13)(13-7)/2 with ri = percentages of subjects with both hSBA titers \>= LLQ against N. meningitis for all serogroups A, C, W and Y and for all serogroup B test strains at Month 1.

Time frame:
From Month 0 to Month 13
Reported as:
Number · Percentage of subjects
The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains.
Percentage of subjectsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Serogroup A- Month 0-2 (LLQ-22.7)26.5238.0198.6238.0557.1227.86
Serogroup A- Month 2-3 (LLQ-22.7)57.6960.9886.9133.4047.0059.13
Serogroup A- Month 3-7 (LLQ-22.7)292.53264.81243.86252.54119.41370.46
Serogroup A- Month 7-13 (LLQ-22.7)256.04214.62217.88446.58343.24436.76
B M14459- Month 0-2 (LLQ-8.0)35.1027.8167.0221.0940.1018.57
B M14459- Month 2-3 (LLQ-8.0)55.4546.0652.3616.5330.8844.90
B M14459- Month 3-7 (LLQ-8.0)228.61196.15117.62206.8484.60325.33
B M14459- Month 7-13 (LLQ-8.0)162.94141.7982.51329.36309.09347.86
B 96217- Month 0-2 (LLQ-8.6)93.5291.00124.7088.2783.0879.10
B 96217- Month 2-3 (LLQ-8.6)85.0380.0295.7758.5552.3374.25
B 96217- Month 3-7 (LLQ-8.6)388.93373.02361.75307.65172.73392.59
B 96217- Month 7-13 (LLQ-8.6)545.92515.49495.00561.47411.36578.42
B NZ98/254- Month 0-2 (LLQ-8.2)30.2725.8448.9222.3731.3320.13
B NZ98/254- Month 2-3 (LLQ-8.2)55.5640.7737.2115.8924.0542.93
B NZ98/254- Month 3-7 (LLQ-8.2)227.81162.8992.78156.6565.46282.91
B NZ98/254- Month 7-13 (LLQ-8.2)142.59105.4090.34242.66257.90277.24
B M07-0241084- Month 0-2 (LLQ-8.9)57.7443.2053.6742.7458.9347.53
B M07-0241084- Month 2-3 (LLQ-8.9)52.4637.1634.0128.3334.4741.65
B M07-0241084- Month 3-7 (LLQ-8.9)213.53151.20111.63190.79110.94251.09
B M07-0241084- Month 7-13 (LLQ-8.9)217.26159.73145.97301.71282.69320.48
Serogroup C- Month 0-2(LLQ-5.2)102.82129.30148.03126.63135.79128.34
Serogroup C- Month 2-3(LLQ-5.2)78.7891.9799.2282.9788.2192.85
Serogroup C- Month 3-7(LLQ-5.2)331.60390.80390.79360.70339.12398.53
Serogroup C- Month 7-13(LLQ-5.2)382.55567.41574.69589.70545.04595.68
Serogroup W-Month 0-2(LLQ-39.6)75.6693.12124.8985.71103.9484.23
Serogroup W-Month 2-3(LLQ-39.6)68.5181.7590.3365.6675.1978.97
Serogroup W-Month 3-7(LLQ-39.6)293.42359.84327.79331.64297.71392.61
Serogroup W-Month 7-13(LLQ-39.6)305.31444.54434.34543.61512.92550.19
Serogroup Y-Month 0-2(LLQ-14.7)36.2576.3199.4467.8384.9267.58
Serogroup Y-Month 2-3(LLQ-14.7)24.5179.3283.2658.8867.7075.50
Serogroup Y-Month 3-7(LLQ-14.7)100.05339.26339.26303.62234.85373.95
Serogroup Y-Month 7-13(LLQ-14.7)125.13425.13389.69520.64454.48537.41
SecondaryNumber of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination.

Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity within 30 minutes after each vaccination. Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).

Time frame:
Within 30 minutes after vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination.
ParticipantsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Any Induration(1st vaccination)000000
Grade 3 Induration(1st vaccination)000000
Any Induration(2nd vaccination)000000
Grade 3 Induration(2nd vaccination)000000
Any Induration(3rd vaccination)000000
Grade 3 Induration(3rd vaccination)000000
Any Induration(4th vaccination)000000
Grade 3 Induration(4th vaccination)000000
Any Induration(5th vaccination)000000
Grade 3 Induration(5th vaccination)000000
Any Erythema(1st vaccination)100010
Grade 3 Erythema(1st vaccination)000000
Any Erythema(2nd vaccination)200100
Grade 3 Erythema(2nd vaccination)000000
Any Erythema(3rd vaccination)010100
Grade 3 Erythema(3rd vaccination)000000
Any Erythema(4th vaccination)010001
Grade 3 Erythema(4th vaccination)000000
Any Erythema(5th vaccination)000000
Grade 3 Erythema(5th vaccination)000000
Any Pain(1st vaccination)1941281713
Grade 3 Pain(1st vaccination)000000
Any Pain(2nd vaccination)1012119149
Grade 3 Pain(2nd vaccination)000000
Any Pain(3rd vaccination)101187513
Grade 3 Pain(3rd vaccination)000000
Any Pain(4th vaccination)2822714817
Grade 3 Pain(4th vaccination)000000
Any Pain(5th vaccination)191612151312
Grade 3 Pain(5th vaccination)000000
Any Nausea(1st vaccination)002122
Grade 3 Nausea(1st vaccination)000000
Any Nausea(2nd vaccination)201100
Grade 3 Nausea(2nd vaccination)000000
Any Nausea(3rd vaccination)202001
Grade 3 Nausea(3rd vaccination)000000
Any Nausea(4th vaccination)202010
Grade 3 Nausea(4th vaccination)000000
Any Nausea(5th vaccination)103101
Grade 3 Nausea(5th vaccination)000000
Any Fatigue (1st vaccination)466121
Grade 3 Fatigue(1st vaccination)000000
Any Fatigue (2nd vaccination)431120
Grade 3 Fatigue(2nd vaccination)000000
Any Fatigue (3rd vaccination)240112
Grade 3 Fatigue(3rd vaccination)000100
Any Fatigue (4th vaccination)211013
Grade 3 Fatigue(4th vaccination)000000
Any Fatigue (5th vaccination)121311
Grade 3 Fatigue(5th vaccination)000000
Any Myalgia(1st vaccination)010000
Grade 3 Myalgia(1st vaccination)000000
Any Myalgia(2nd vaccination)001031
Grade 3 Myalgia(2nd vaccination)000000
Any Myalgia(3rd vaccination)000100
Grade 3 Myalgia(3rd vaccination)000000
Any Myalgia(4th vaccination)000010
Grade 3 Myalgia(4th vaccination)000000
Any Myalgia(5th vaccination)041010
Grade 3 Myalgia(5th vaccination)000000
Any Arthralgia(1st vaccination)000000
Grade 3 Arthralgia(1st vaccination)000000
Any Arthralgia(2nd vaccination)000000
Grade 3 Arthralgia(2nd vaccination)000000
Any Arthralgia(3rd vaccination)000000
Grade 3 Arthralgia(3rd vaccination)000000
Any Arthralgia(4th vaccination)000000
Grade 3 Arthralgia(4th vaccination)000000
Any Arthralgia(5th vaccination)000000
Grade 3 Arthralgia(5th vaccination)000000
Any Headache(1st vaccination)231110
Grade 3 Headache(1st vaccination)000000
Any Headache(2nd vaccination)312111
Grade 3 Headache(2nd vaccination)000000
Any Headache(3rd vaccination)212011
Grade 3 Headache(3rd vaccination)000000
Any Headache(4th vaccination)320011
Grade 3 Headache(4th vaccination)000000
Any Headache(5th vaccination)210001
Grade 3 Headache(5th vaccination)000000
Any Chills(1st vaccination)011022
Grade 3 Chills(1st vaccination)000000
Any Chills(2nd vaccination)111100
Gradec3 Chills(2nd vaccination)000000
Any Chills(3rd vaccination)110000
Grade 3 Chills(3rd vaccination)000000
Any Chills(4th vaccination)110000
Grade 3 Chills(4th vaccination)000000
Any Chills(5th vaccination)110000
Grade 3 Chills(5th vaccination)000000
Any Appetite Loss(1st vaccination)000000
Grade 3 Appetite Loss(1st vaccination)000000
Any Appetite Loss(2nd vaccination)000000
Grade 3 Appetite Loss(2nd vaccination)000000
Any Appetite Loss(3rd vaccination)000000
Grade 3 Appetite Loss(3rd vaccination)000000
Any Appetite Loss(4th vaccination)000000
Grade 3 Appetite Loss(4th vaccination)000000
AnyAppetiteLoss(5th vaccination)000000
Grade 3 Appetite Loss(5th vaccination)000000
Fever(1st vaccination)000000
Fever(2nd vaccination)000000
Fever(3rd vaccination)000000
Fever(4th vaccination)000000
Fever(5th vaccination)000000
Pain/Fever prevention(1st vaccination)000000
Pain/Fever prevention(2nd vaccination)020000
Pain/Fever prevention(3rd vaccination)100000
Pain/Fever prevention(4th vaccination)000000
Pain/Fever prevention(5th vaccination)000000
Pain/Fever treatment(1st vaccination)001000
Pain/Fever treatment(2nd vaccination)100001
Pain/Fever treatment(3rd vaccination)000000
Pain/Fever treatment(4th vaccination)010000
Pain/Fever treatment(5th vaccination)000010
SecondaryNumber of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination.

An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a participant and/or parent/legal guardian who has signed the informed consent. Number of participants reporting any unsolicited AE within 30 minutes after each vaccination.

Time frame:
Within 30 minutes after vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination.
ParticipantsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Dizziness301201
Presyncope210000
Syncope011010
Injection site pain100001
Asthenia000001
Dyspnoea100000
Fatigue000010
Headache000010
Hypoaesthesia000010
Injection site bruising100000
Injection site warmth010000
Pain000010
Paraesthesia100000
Pruritus allergic001000
SecondaryNumber of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination.

The number of participants reporting unsolicited AEs and possibly or probably related unsolicited AEs were assessed.

Time frame:
Day 1 through Day 30 after any vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination.
ParticipantsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Any AE(s)146148937697104
Possibly or Probably Related AE(s)253123161827
SecondaryNumber of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7.

Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity from Day 1 (6 hours) to Day 7 after any meningococcal vaccination is reported.

Time frame:
At Day 1 (6 hours) to Day 7 after vaccination
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7.
ParticipantsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Any AE225228153131151157
Any Local AE224227148129148156
Any Systemic AE201201143117134143
Any Pain (1st vacc)21322314212680146
Grade 3 Pain (1st vacc)91321006
Any Pain (2nd vacc)32341224113551
Grade 3 Pain (2nd vacc)0150110
Any Pain (3rd vacc)193185382616133
Grade 3 Pain (3rd vacc)1170005
Any Pain (4th vacc)79771910644138
Grade 3 Pain (4th vacc)1001009
Any Pain (5th vacc)8380584811964
Grade 3 Pain (5th vacc)0110111
Any Erythema (1st vacc)23211611123
Grade 3 Erythema (1st vacc)011002
Any Erythema (2nd vacc)3581172
Grade3Erythema(2ndvacc)001030
Any Erythema (3rd vacc)322702019
Grade3Erythema(3rdvacc)260001
Any Erythema (4th vacc)11010013
Grade3Erythema(4thvacc)000104
Any Erythema (5th vacc)1110110
Grade3Erythema(5thvacc)000010
AnyInduration(1st vacc)21201213319
Grade3Induration(1vacc)000101
AnyInduration(2nd vacc)22100112
Grade3Induration(2vacc)000000
AnyInduration(3rd vacc)241700120
Grade3Induration(3vacc)200000
AnyInduration(4th vacc)23010014
Grade3Induration(4vacc)000101
AnyInduration(5th vacc)2312161
Grade 3 Induration(5th vacc)000110
Any Fatigue (1st vacc)12612184686876
Grade 3 Fatigue(1st vacc)774334
Any Fatigue (2nd vacc)616464406449
Grade 3 Fatigue(2nd vacc)034210
Any Fatigue (3rd vacc)1069644323255
Garde 3 Fatigue(3rd vacc)451011
Any Fatigue (4th vacc)505637513573
Grade 3 Fatigue(4th vacc)230523
Any Fatigue (5th vacc)625937415146
Grade3Fatigue(5th vacc)124063
Any Headache (1st vacc)1039265526364
Grade3Headache(1stvacc)435223
Any Headache (2nd vacc)674770366341
Grade3Headache(2ndvacc)123242
Any Headache (3rd vacc)907642283053
Grade3Headache(3rdvacc)341030
Any Headache (4th vacc)493526442652
Grade3Headache(4thvacc)330204
Any Headache (5th vacc)644033335237
Grade3Headache(5thvacc)112122
Any Myalgia (1st vacc)625339343340
Grade3Myalgia(1st vacc)242203
Any Myalgia (2nd vacc)152027153718
Grade3Myalgia(2nd vacc)031110
Any Myalgia (3rd vacc)524013101334
Grade3Myalgia(3rd vacc)220022
Any Myalgia (4th vacc)172011261339
Grade3Myalgia(4th vacc)111202
Any Myalgia (5th vacc)162619122119
Grade3Myalgia(5th vacc)010011
AnyAppetite Loss(1vacc)413328221418
Grade3AppetiteLoss(1vacc)230000
AnyAppetiteLoss(2vacc)17111512199
Grade3AppetiteLoss(2vacc)010020
AnyAppetiteLoss(3vacc)2828771117
Grade3AppetiteLoss(3vacc)101010
AnyAppetiteLoss(4vacc)11104131123
Grade3AppetiteLoss(4vacc)000000
AnyAppetiteLoss(5vacc)181499227
Grade3AppetiteLoss(5vacc)001000
Any Nausea (1st vacc)423628172621
Grade 3 Nausea(1stvacc)100001
Any Nausea (2nd vacc)171520102615
Grade 3 Nausea(2nd vacc)000000
Any Nausea (3rd vacc)3524108421
Grade 3 Nausea(3rd vacc)000000
Any Nausea (4th vacc)21139111423
Grade 3 Nausea(4th vacc)100000
Any Nausea (5th vacc)16158112112
Grade 3 Nausea(5th vacc)000000
Any Chills (1st vacc)453641242740
Grade 3 Chills(1stvacc)101121
Any Chills (2nd vacc)172626123215
Grade 3 Chills(2ndvacc)011000
Any Chills(3rd vacc)3333971222
Grade 3 Chills(3rdvacc)110010
Any Chills(4thvacc)11111012931
Grade 3 Chills(4thvacc)200001
Any Chills (5th vacc)192317112213
Grade 3 Chills(5vacc)000100
Fever (1st vacc)545123
Fever (2nd vacc)264293
Fever (3rd vacc)632044
Fever (4th vacc)020307
Fever (5th vacc)512031
Pain/Fever prevention(1)28342126534
Pain/Fever prevention(2)57185247
Pain/Fever prevention(3)323432321
Pain/Fever prevention(4)65319325
Pain/Fever prevention(5)5941263
Pain/Fever treatment(1)31452732631
Pain/Fever treatment(2)34203294
Pain/Fever treatment(3)383724223
Pain/Fever treatment(4)74222227
Pain/Fever treatment(5)3823292
Any Arthralgia(1st vacc)251413171214
Grade3Arthralgia(1stvacc)010012
Any Arthralgia (2nd vacc)71110987
Grade3Arthralgia(2ndvacc)000101
Any Arthralgia(3rd vacc)16743611
Grade3Arthralgia(3rdvacc)010000
Any Arthralgia(4th vacc)810510718
Grade3Arthralgia(4thvacc)100002
Any Arthralgia(5th vacc)89861111
Grade3Arthralgia(5thvacc)000000
SecondaryNumber of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal

The number of participants reporting any SAE, possibly or probably related SAE(s), medically-attended AEs, AEs leading to premature withdrawal, AEs leading to death, AEs leading to hospitalization and AEs leading to dose reduction, interruption and delay in study vaccination during the entire study period is reported.

Time frame:
During the entire study period (Month 0 to Month 13)
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal
ParticipantsrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Any SAE(s)938726
Possibly or Probably Related SAE(s)011000
Medically Attended AE(s)1039768576779
AE(s) leading to premature withdrawal264213
AE(s) leading to Death000000
AE(s) leading to Hospitalization917616
AE(s)leadingtodosereduction,interruption,vaccdelay887245

Adverse events

Collected over Solicited AEs were collected from day 1 to day 7, Unsolicited AEs were collected from day 1 to day 30, SAEs were collected throughout the entire study period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rMenB_0_2 Group0/228 (0%)9/228 (3.9%)226/228 (99.1%)
ABCWY_ 0_2 Group0/231 (0%)3/231 (1.3%)229/231 (99.1%)
ABCWY_0_1 Group0/155 (0%)8/155 (5.2%)153/155 (98.7%)
ABCWY_0_6 Group0/134 (0%)7/134 (5.2%)131/134 (97.8%)
ABCWY_0_11 Group0/151 (0%)2/151 (1.3%)151/151 (100%)
ABCWY_0_2_6 Group0/159 (0%)6/159 (3.8%)158/159 (99.4%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
AppendicitisInfections and infestations1/2280/2312/1550/1340/1510/159
Iron deficiency anaemiaBlood and lymphatic system disorders2/2280/2310/1550/1340/1510/159
Abdominal painGastrointestinal disorders0/2280/2311/1551/1340/1510/159
Crohn's diseaseGastrointestinal disorders0/2280/2310/1551/1340/1510/159
FatigueGeneral disorders0/2280/2310/1551/1340/1510/159
GastroenteritisInfections and infestations0/2280/2310/1551/1340/1510/159
TonsillitisInfections and infestations0/2280/2310/1551/1340/1510/159
Type 1 diabetes mellitusMetabolism and nutrition disorders0/2280/2310/1551/1340/1510/159
Mental disorderPsychiatric disorders0/2280/2310/1551/1340/1510/159
Tooth extractionSurgical and medical procedures0/2280/2310/1551/1340/1510/159
Most frequent other events
Showing 10 of 21
Most frequent other events
EventrMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 Group
Injection site painGeneral disorders221/228225/231148/155129/134148/151154/159
FatigueGeneral disorders169/228165/231119/15598/134105/151120/159
HeadacheNervous system disorders165/228149/231114/15593/134110/151117/159
Injection site erythemaGeneral disorders131/228131/23180/15580/13489/15197/159
Injection site indurationGeneral disorders110/22898/23167/15553/13470/15185/159
MyalgiaMusculoskeletal and connective tissue disorders103/22899/23169/15554/13465/15181/159
ChillsGeneral disorders80/22876/23161/15540/13462/15170/159
NauseaGastrointestinal disorders74/22868/23151/15547/13456/15162/159
Decreased appetiteMetabolism and nutrition disorders69/22864/23145/15543/13445/15152/159
Upper respiratory tract infectionInfections and infestations53/22858/23137/15531/13435/15137/159

Baseline characteristics

Age, Continuous
Age, Continuous(Years)rMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 GroupTotal
Mean14.5 ± 3.0914.2 ± 3.1714.4 ± 3.0114.4 ± 3.0614.5 ± 3.114.3 ± 3.1614.4 ± 3.1
Sex: Female, Male
Sex: Female, Male(Participants)rMenB_0_2 GroupABCWY_ 0_2 GroupABCWY_0_1 GroupABCWY_0_6 GroupABCWY_0_11 GroupABCWY_0_2_6 GroupTotal
Female130119101768996611
Male9811356586364452
08

Study locations

32 sites
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
  • GSK Investigational Site
    Melbourne, Florida 32934, United States
  • GSK Investigational Site
    Augusta, Kansas 67010, United States
  • GSK Investigational Site
    Niles, Michigan 49120, United States
  • GSK Investigational Site
    Saint Paul, Minnesota 55108, United States
  • GSK Investigational Site
    Bellevue, Nebraska 68005, United States
  • GSK Investigational Site
    Omaha, Nebraska 68114, United States
  • GSK Investigational Site
    Binghamton, New York 13901, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    Dayton, Ohio 45406, United States
  • GSK Investigational Site
    Charleston, South Carolina 29414, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Espoo, 02230, Finland
  • GSK Investigational Site
    Helsinki, 00100, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland
  • GSK Investigational Site
    Jarvenpaa, 04400, Finland
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90200, Finland
  • GSK Investigational Site
    Pori, 28100, Finland
  • GSK Investigational Site
    Seinajoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Vantaa, 01300, Finland
  • GSK Investigational Site
    Debica, 39200, Poland
  • GSK Investigational Site
    Gdansk, 80 542, Poland
  • GSK Investigational Site
    Gdansk, 80-546, Poland
  • GSK Investigational Site
    Lodz, 91347, Poland
  • GSK Investigational Site
    Osielsko, 86031, Poland
  • GSK Investigational Site
    Siemianowice Slaskie, 41 103, Poland
  • GSK Investigational Site
    Warszawa, 01809, Poland
  • GSK Investigational Site
    Wroclaw, 50368, Poland
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in May 2015, 9 months.

Results were first posted in Jul 2017, 2 years 1 month after primary completion. A results delay was requested in May 2015.

Of 18 phase 2 interventional studies under Meningococcal Infections, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 17. This study's 9 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2014
First posted
Aug 8, 2014
StartActual
Aug 21, 2014
Primary completionActual
May 22, 2015
CompletionActual
Mar 3, 2016
Results delay requested
May 29, 2015
Results first posted
Jul 21, 2017
Last update
Jun 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02212457
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 8, 2014
Start date
Aug 21, 2014
Primary completion
May 22, 2015
Completion
Mar 3, 2016
Results posted
Jul 21, 2017
Last update
Jun 27, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 4CMenB vaccine · Meningococcal pentavalent vaccine

Start the discussion